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ABSTRACT 
 
Sean T. Bailey:  Inhibition of compensatory survival and proliferative pathway activation 
induced by mTOR inhibition in Renal Cell Carcinoma 
(Under the direction of William Y. Kim, M.D.) 
 
 
The mammalian target of rapamycin (mTOR) is a key regulator of tumor 
progression in a variety of cancers and has been shown to be dysregulated in renal cell 
carcinoma (RCC).  mTOR exists in two independent complexes.  The mTORC1 
complex consists of mTOR, Raptor, and GβL, while the mTORC2 complex consists of 
mTOR, Rictor, and GβL.  Currently there are two FDA approved rapamycin derivatives 
(rapalogs) for the treatment of advanced renal cell carcinoma (RCC).  Allosteric mTOR 
inhibition (i.e. rapalogs) results in the release of negative feedback inhibition on the 
PI3K/AKT survival-signaling pathway as well as upregulates the metabolically protective 
process known as autophagy.  Furthermore, catalytic mTOR inhibitors attenuate 
mTORC1 downstream signaling nodes more completely, but also diminishes mTORC2 
mediated AKT survival signals induced by allosteric mTOR inhibitors.  Additionally, it 
has been demonstrated, that mTOR inhibition results in activation of the MEK/MAPK 
signaling cascade. Based on this information, we wished to interrogate the molecular 
and biological consequences of inhibiting mTOR pharmacologically and genetically in 
the context of RCC. 
We first asked what was the effect of allosteric versus catalytic mTOR inhibition 
in several conventional human RCC cell lines and novel patient derived xenograft cell 
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lines on mTORC1 and mTORC2 signaling.  We saw that only 1) catalytic mTOR 
inhibition decreased pAKTS473 expression, 2) that both allosteric and catalytic mTOR 
inhibition increase pERKT202/Y204 expression, and 3) combined MEK and mTOR 
inhibition induced cell death better than single pathway inhibition alone.  Finally, we 
noted that hierarchal clustering of KIRC_TCGA RPPA (reverse phase protein array) 
data by markers of mTOR and MEK activation revealed subclasses respective to mTOR 
and MEK/ERK signaling with significant differences in clinical outcome. 
We next asked how allosteric versus catalytic mTOR inhibition affected the 
metabolically conserved process known as autophagy.  While both allosteric and 
catalytic inhibition increased autophagic flux; catalytic mTOR inhibition did so to a 
greater degree.  To determine if this was due to catalytic mTOR inhibitors’ ability to 
attenuate mTORC2 signaling we assessed autophagic flux in cell lines stably 
expressing shRNAs targeting Raptor or Rictor, essential components for mTORC1 and 
mTORC2 signaling, respectively.  Knock-down of Raptor results in an increase in 
autophagic flux, however knock-down of Rictor also increases autophagic flux 
demonstrating that the increased autophagic flux induced by catalytic mTOR inhibition 
is partly due to inhibition of mTORC2.  Finally, we show that catalytic mTOR inhibition in 
conjunction with autophagy inhibition decreases cellular proliferation while augmenting 
apoptosis. Together these data support that there are differences in levels of activation 
of compensatory survival pathways in the context of allosteric and catalytic mTOR 
inhibition.
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CHAPTER 1 
INTRODUCTION:  TARGETING MTOR IN RENAL CELL CARCINOMA 
1.1	   Renal	  cell	  carcinoma	  
 
 Renal cell carcinoma (RCC) is a heterogeneous disease of epithelial renal origin 
and ranks 6th and 8th amongst other cancer types in men and women, respectively [1].   
In 2013, RCC occurrences accounted for an estimated 40,000 and 25,000 new cases in 
men and women, respectively [1].  Together, estimated deaths from RCC tallied near 
14,000 for men and women combined [1].  RCC typically presents as one of several 
histological subtypes:  clear cell, type I or II papillary, chromophobe, or oncocytoma [2].  
The heterogeneous nature of RCC reflects the differences in genetics and biology, and 
these differences can be linked to unique genetic lesions [2].  Interestingly, the genetic 
basis for the different histological subtypes of RCC can be linked not only through 
inherited cancer syndromes (Table 1.1), but also occurrences of sporadic mutations of 
the same loci coupled with the corresponding familial cancer syndromes (Table 1.1).  Of 
the different subtypes of RCC, clear cell renal cell carcinoma (ccRCC) encompasses 
~65% of reported cases [3].  Histological features consist of hyperchromatic nuclei and 
a distinct clear cytoplasm caused by an accumulation of cholesterol with a recent 
molecular link to hypoxia-inducible factor 1 α (HIF1α) transcriptional regulation of very 
low-density lipoprotein receptor (VLDL-R) [4,5].  Furthermore, ccRCC development is 
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tightly associated with mutations in the von Hippel-Lindau (VHL) tumor suppressor 
gene, and will be the main RCC subtype focused on within this document [3,6]. 
 
Table 1.1:  Sporadic and hereditary RCC characteristics:  Histological, incidence, 
genetic lesion, and inherited syndrome correlation of RCC  
1.1.1	   VHL	  and	  ccRCC	  relevance	  
 
The VHL gene has been shown to function as a tumor suppressor through both 
functional and genetic evidence [7].  VHL disease effects 1:35,000 individuals and is an 
autosomal dominant cancer syndrome consisting of a spectrum of tumors, but most 
commonly ccRCC, hemangioblastoma, and pheochromocytoma [6].  Interestingly, there 
are direct genotype-phenotype correlations for VHL disease patients.  Specifically, 
Type1 or Type 2B VHL disease patients present with clinical manifestations associated 
with RCC.  It’s important to note, in the case of inherited ccRCC, that loss of 
heterozygocity of the remaining wild-type allele results in renal cysts followed by tumor 
initiation and these lesions are multifocal and can occur bilaterally in both kidneys [8]. 
Sporadic mutations and hypermethylation of VHL may also occur in individuals 
that are wild-type for both VHL alleles, and interestingly occurs in ~90% of patients with 
Sporadic RCC Hereditary RCC 
Histology Incidence (%) Gene Inherited Syndrome Gene 
ccRCC ~65 VHL VHL disease VHL 
Papillary ~15-20 MET HPRC                             HLRCC 
MET                              
FH 
Chromophobe 5 Birt-Hogg-Dubé           syndrome BHD 
Oncocytoma 4 Birt-Hogg-Dubé           syndrome BHD 
Collecting Duct <1 
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sporadic RCC [9].  As with inherited ccRCC, loss of the remaining wild-type allele is 
necessary for sporadic tumor formation.  However, unlike hereditary ccRCC’s multi-
focal presentation, sporadic ccRCC tumors form as focal lesions in a unilateral fashion 
[8]. 
1.1.2	   VHL	  	  and	  HIFα 	  regulation1	  	  
 
The VHL gene is composed of 3 exons located on the short arm of chromosome 3 
and codes for the protein VHL (pVHL).  pVHL expression is not restricted to tissues 
effected by VHL disease [10].  pVHL functions in a ubiquitin ligase complex consisting 
of several proteins:  elongin B, elongin C, Cul2, and Rbx1 [7].  When functional, and in 
normoxic cellular environments, this complex targets HIFα proteins for proteosomal 
degradation [11] (Figure 1.1). 
                                            
1 1.1.2-1.1.4 modified from Jonasch E, Futreal A, Davis I, Bailey S, Kim WY, Brugarolas J, Giaccia AJ, 
Kurban G, Pause A, Frydman J, Zurita A, Rini BI, Sharma P, Atkins M, Walker C, Rathmell.  State-of-the-
science: An update on renal cell carcinoma.  Molecular Cancer Research. (2012)  
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Figure 1.1:  VHL regulation of HIFα.  Functional pVHL post transcriptionally 
ubiquitinates HIFα targeting it for proteosomal degradation. 
 
However, in the context of hypoxia, hereditary VHL disease associated RCC or sporadic 
ccRCC this negative regulation of HIFα is perturbed (Figure 1.2). 
Normoxia 
P 
OH 
    pVHL 
Elongin B Cul2 
Rbx1 
Ubiquitin 
Ligase 
complex 
 
Elongin C 
Ub 
P 
OH 
Proteosomal Degradation of HIF-α 
Ub Ub Ub 
HIF-α 
HIF-α 
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Figure 1.2:  HIFα stabilization.  Under hypoxic conditions or when pVHL is non-
functional HIFα is not hydroxylated resulting in perturbation of pVHL binding and 
subsequent HIFα stabilization.  Stabilized HIFα translocates to the nucleus to form a 
dimer with HIFβ and activate transcription of HIFα target genes. 
  
The interaction between HIFα and pVHL is mediated by an enzymatic, post-
translational hydroxylation of HIFα on conserved prolyl residues (by a family of HIFα 
prolyl hydroxylases (PHDs or EGLNs).  In keeping with the notion that regulation of HIF 
is an important function of pVHL, the majority of disease associated VHL mutations are 
predicted to abolish the interaction between pVHL and HIFα resulting in an upregulation 
of HIFα target genes [12]. 
1.1.3	   HIF	  and	  HIF	  target	  genes	  	  	  	  	  
 
The HIF proteins are a family of transcription factors that contain a basic helix-
loop-helix domain and function in a heterodimeric complex [13]. There are three known 
Hypoxia pVHL Inactivation 
P 
OH 
P 
    pVHL 
P 
HIFα Stabilization 
P 
OH 
HIF-α 
HIF-α 
HIF-α 
HIF-α 
HIF-α HIF-β 
Transcriptional Activation 
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HIFα subunits (HIF1α, HIF2α, HIF3α) which heterodimerize with their binding partner 
ARNT (HIF1β) to transcriptionally regulate target genes containing hypoxia response 
elements (HREs).  HIF1α and HIF2α, are best characterized and are known to regulate 
transcriptional programs associated with cellular and physiological adaptation to 
hypoxia such as erythropoietin (EPO), vascular endothelial growth factor (VEGF), and 
carbonic anhydrase 9 (CA9), amongst others [14,15].  While there is significant overlap 
in genes that are transcriptionally activated by HIF1α and HIF2α, each HIF family 
member is thought to also transactivate unique target genes [16].  For example, HIF1α 
has been linked to regulating genes in pathways associated with glycolytic metabolism 
and autophagy such as, solute carrier family 2 (facilitated glucose transporter), member 
1 (SLC2A1) also known as glucose transporter protein type 1 (GLUT1), pyruvate 
dehydrogenase kinase1 (PDK1), lactate dehydrogenase A (LDHA), and 
BCL2/Adenovirus E1B 19kDa Interacting Protein 3 (BNIP3) [17].  HIF2α is uniquely 
responsible for transcriptionally activating genes associated with proliferation and de-
differentiation, transforming growth factor alpha (TGFα), CCND1 (Cyclin D1), and Oct4, 
respectively [13,18,19]. 
1.1.4	   HIF1-­‐α 	  and	  HIF2-­‐α 	  contribution	  in	  ccRCC	  
 
Early in vitro and cell line xenograft studies suggested that while HIF2α is both 
necessary and sufficient for the growth of transformed ccRCC cell lines [20-22] HIF1α is 
not [23], indicating that HIF1α is dispensable for ccRCC growth.  However, it appears 
that HIF1α is not merely dispensable in the context of RCC but actually functions as a 
tumor suppressor gene. Several lines of evidence support this hypothesis.  First, 
targeted exon sequencing of ccRCC has demonstrated (albeit rarely) inactivating 
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mutations in HIF1α [24], while copy number analysis of ccRCC cell lines and primary 
tumors suggest that the HIF1α locus is frequently lost along with the long arm of 
chromosome 14 (14q) [25].  Secondly, while all VHL defective clear cell renal cell 
carcinomas appear to overexpress HIF2α, about one third of these tumors appear to 
lack HIF1α expression as well [26].  Finally, functional studies in vitro and in vivo 
suggest that over expression of HIF1α in VHL wild type cells restrains tumor growth 
while suppression of HIF1α in VHL deficient cells enhances tumor growth [18,25,27].  
Together these studies show support for HIF1α as tumor suppressor gene in renal 
cancer development and HIF2α as a key driver for renal cancer progression. 
While there are a number of reasons to explain the contrasting properties of HIF1α 
and HIF2α in ccRCC pathogenesis, one intriguing observation is that HIF1α and HIF2α 
have opposing roles on the regulation of c-Myc activity.  Specifically HIF1α acts to 
suppress c-Myc activity while HIF2α promotes the transactivation or transrepression of 
c-Myc specific target genes [26,28,29].  In keeping with this notion, ccRCC tumors that 
exclusively express HIF2α have increased proliferation rates. Furthermore, intriguingly, 
a subset of clear cell RCC tumors appear to have copy number amplification of 8q24, 
where c-Myc resides [30,31]. 
1.2	   Therapeutic	  options	  for	  advanced	  ccRCC	  
 
Unlike some cancers capable of being treated with radiation or chemotherapy, 
advanced RCC unfortunately does not respond to such treatment regimens [8].  This 
clinical observation has warranted efforts in selecting compounds capable of combating 
advanced RCC.  Prior to the past 10 years of targeted therapeutic advancement, 
conventional treatment of advanced RCC was solely with immunotherapies, interferon 
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alfa (INF-α) and interleukin-2 (IL-2) [32].  Within the past 10 years, there have been 
seven targeted therapeutics approved by the Food and Drug Administrations (FDA) for 
treating advanced RCC.  These seven drugs consist of small molecule receptor tyrosine 
kinase (RTK) inhibitors and biologicals (i.e. monoclonal antibodies) targeting angiogenic 
pathways, and targeted agents directed at inhibiting the mammalian target of rapamycin 
(mTOR) (Table 1.2) [33]. 
 
Table 1.2:  FDA approved targeted agents for treating advanced RCC. 
Interestingly, patients treated with inhibitors targeting vascular endothelial growth 
factor receptor (VEGF-R) appear to have the best response rates, with allosteric mTOR 
inhibitors (everolimus and temsirolimus) having the most modest responses, yet still 
prolonging overall survival [3].  The modest response rates seen with allosteric mTOR 
inhibition warrants a better understanding of RCC biology in the context of allosteric 
mTOR inhibition and/or inhibitors capable of more complete inhibition of mTOR.  
However, there is still much needed understanding of the consequences of mTOR 
inhibition in the context of RCC.  Henceforth, advanced efforts to better understand the 
Targetd Agents for Treating Advanced RCC 
Therapeutic Class Date Approved Molecular Target 
Sorafenib TKI 2005 VEGFR, PDGFR, KIT, RAF 
Suntinib TKI 2006 VEGFR, PDGFR, KIT, FLT3, RET 
Temsirolimus Rapamycin Derivative 2007 mTOR 
Everolimus Rapamycin Derivative 2007 mTOR 
Bevacizumab Monoclonal Antibody 2009 VEGF 
Pazopanib TKI 2009 VEGFR, PDGFR, FGFR KIT 
Axitinib TKI 2012 VEGFR, PDGFR, KIT 
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biologic consequences of mTOR inhibition has elucidated potential targetable 
compensatory survival pathways capable of increasing efficacy and modest response 
rates. 
1.3	   mTOR	  signaling	  
 
mTOR is a serine/threonine kinase within the phophoinositide 3-kinase (PI3K)-
related kinase family and is homologous to yeast TOR [34].  mTOR is one of the most 
widely studied nutritional sensors for cellular and organismal integrity.  mTOR functions 
in two distinct complexes known as mTORC1 and mTORC2, and discoveries alluding to 
the realization that mTOR regulates signal transduction in two unique complexes was 
made possible by the observation that mTOR was a unique target of rapamycin, hence 
the acronym “TOR”.  Rapamycin inhibits mTORC1 in an allosteric manner binding to 
FK506-binding protein of 12 kDa (FKBP12-rapamycin) to bind to the FKBP12-
rapamycin binding domain (FRB) of mTOR.  A recent co-crystal structure of a truncated 
form of mTOR and mLST8 revealed that the FRB domain acts as a gatekeeper granting 
access of mTOR substrates to the catalytic-active site of mTOR.  Of additional 
importance, the FRB domain of mTOR cannot be accessed by FKBP12-rapamycin 
resulting in ineffective inhibition of downstream mTORC2 signaling [35].  More detail of 
the effects of rapamycin on mTORC1 and mTORC2 signaling will be discussed in later 
sections of this document. 
mTORC1 and mTORC2 both contain the catalytic subunit mTOR, tti1/tel2 complex, 
mammalian lethal with sec-13 protein 8 (mLST8), and DEP domain containing mTOR-
interacting protein (DEPTOR).  However, the two complexes differ in several protein 
components.  The proline-rich AKT substrate 40 kDa (PRAS40) and regulatory-
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associated protein of mammalian target of rapamycin (Raptor) are distinct to mTORC1, 
and mammalian stress-activated map kinase-interacting protein1 (mSin1), protein 
observed with Rictor1 and 2 (protor1/2), and rapamycin-insenstive companion of mTOR 
(Rictor) are specific to mTORC2 [36].  Importantly, Raptor and Rictor serve as essential 
components for mTORC1 and mTORC2 signaling, respectively [37,38]. 
At this time, regulation and function of mTORC1 is understood in more detail than 
mTORC2, most likely due to the use of rapamycin and its specificity to target the 
mTORC1 pathway.  Specifically, mTORC1 has been described to act as signal 
transduction hub processing extracellular and intracellular cues such as hypoxia, energy 
levels, growth factors, and nutrients to regulate macromolecular biosynthesis, cell cycle 
progression, cellular growth, autophagy, and metabolism (Figure 1.3) [36]. 
 
Figure 1.3:  mTOR complexes – regulation and function. 
The discovery that the tuberous sclerosis 1 (hamartin) and 2 (tuberin) complex (TSC1/2) 
functions upstream of mTORC1 to negatively regulate its activity is a hallmark 
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connecting augmented mTOR signaling to cancer [39].  Inactivation of TSC1/2 function 
correlates with the hereditary TSC syndrome which can manifest an array of different 
tumor types [40].  Hypoxic cellular conditions through regulated in development and 
DNA damage responses 1 protein (REDD1) and high AMP:ATP ratios through AMP-
activated protein kinase (AMPK) directly activate TSC1/2 [41].  Active TSC1/2 
negatively regulates mTORC1 through its GTPase-activating protein (GAP) activity to 
inhibit Ras homolog enriched in brain (Rheb) GTPase.  In contrast, growth factors 
through stimulation of MEK/ERK and PI3K/AKT signaling cascades are capable of 
inhibiting TSC1/2 leading to a GTP bound activated Rheb to activate mTORC1 [36].  
Interestingly, nutrient signaling (i.e. amino acids) dependent activation of mTORC1 does 
not appear to rely upon signaling through the TSC1/2 complex, and also appears to be 
the only essential extracellular signaling factor able to activate mTORC1 in isolation 
[42]. 
Activated mTORC1 is responsible for directly phosphorylating several effectors 
involved in anabolic processes such as protein synthesis, lipid biogenesis, and 
metabolism [36].  mTOR also negatively regulates autophagy and lysosome biogenesis.  
Interestingly, lysosomes and the enzymes found within their vesicles are essential 
components of the autophagic machinery.   
The best understood effectors of mTORC1 are S6 kinase 1 (S6K1) a member of 
the protein kinase A/protein kinase G/protein kinase C (AGC) protein family, and 
eukaryotic translation initiation factor 4E (eiF4E)-binding protein 1 (4E-BP1), which are 
both involved in translational regulation [43].  It’s important to note, that active mTORC1 
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is part of a negative feedback loop involving RTKs responsible for regulating PI3K/AKT 
signaling (Figure 1.4) [44]. 
 
 
Figure 1.4:  mTORC1 and mTORC2 signaling.  Distinct signaling nodes specific to 
mTORC1 and mTORC2.  mTORC1 phosphorylates S6K resulting in a negative 
feedback loop initiated by S6K mediated downregulation of IRS-1.  Downregulation of 
IRS-1 regulates RTK mediated PI3K signaling.  mTORC2 phosphorylates various AGC 
kinases:  AKT, PKCα, SGK1. GF, growth factors; RTK, receptor tyrosine kinase. 
  
One, well studied mechanism, is through insulin ligand signaling through insulin 
receptor substrate 1 (IRS-1).  Kobayashi and colleagues demonstrated that active 
mTORC1 signaling through downstream effector, S6K1, can downregulate IRS-1 and 
this may occur through S6K phosphorylation of IRS-1 and subsequent subcellular 
relocation of IRS-1.  The posttranslational phosphorylation of IRS-1 is thought to re-
localize IRS-1, targeting it for proteosomal degradation and leading to subsequent 
decreases in PI3K/Akt signaling [45,46].  
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Aside from enhancing various anabolic processes, mTOR is also responsible for 
negatively inhibiting autophagy.  Autophagy is a homeostatic process involving the 
catabolism of aggregated proteins and damaged mitochondria to essentially recycle 
necessary building blocks for cellular homeostasis [47].  Recently, mTORC1 has been 
shown to inhibit autophagy through the direct phosphorylation of an essential autophagy 
regulating protein (ATG) known as Unc-51 like autophagy activating kinase 1 (ULK1) at 
Ser 757 [48,49].  Autophagy is activated in conditions of low nutrients, hypoxia, low 
energy, and various cellular stresses and will be discussed in more detail in a later 
section of this document [50-52].  
As mentioned before, mTOR is also the catalytic kinase within the mTORC2 
complex, and this complex also appears to be sensitive to hormones (i.e. insulin), 
growth factors, and nutrients (amino acids) [53].  In conjunction with mTORC1, 
mTORC2 also regulates cellular metabolism, but autonomously regulates cytoskeletal 
organization and cell survival pathways [36].  Like mTORC1, mTORC2 is also capable 
of phosphorylating several members of the AGC protein family (Figure 1.4) [54].  
mTORC2 is responsible for phosphorylating serum/glucocorticoid regulated kinase 1 
(SGK1) and AKT within their hydrophobic motifs [55,56].  Furthermore, ablation of 
mTORC2 activity by knock-down of Rictor decreases expression of phosphorylated N-
myc downstream regulated gene 1 protein (NDRG1) at Thr 346, a direct substrate of 
SGK1 [55,57].   It has also been shown that growth factors are dispensable for 
mTORC2 phosphorylation of AKT at Ser 473 and protein kinase C-alpha (PKCα) at Ser 
657, two additional AGC protein kinases capable of regulating cell survival and 
cytoskeletal organization, respectively (Figure 1.4) [38,58].    
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Furthermore, work within the mTOR field has demonstrated that loss of the TSC1/2 
complex attenuates mTORC2 signaling while elevating mTORC1 activity [58].  
Needless to say there is not a clear mechanistic understanding of how mTORC2 is 
regulated, but it is important to note that the regulation of mTORC2 activity is complex 
and an area of much needed study.  For example, mTORC2 activity was shown to be 
required for prostate cancer development in mice harboring a phosphatase and tensin 
homolog (PTEN) deletion arguing for the development of compounds specifically 
inhibiting mTORC2 activity [59]. 
As with the important discovery that mTOR is the functional target of rapamycin 
[34] and the dogma surrounding mTORC2’s insensitivity to rapamycin [38], it is also 
important to note the contrasting observation that treatment with rapamycin over 
prolonged duration or within specific cellular context is capable of inhibition of mTORC2 
[60,61]. 
One can see that the majority of research devoted to understanding mTOR 
signaling has been through the understanding of mTORC1, and this is due to the 
pharmacological tool, rapamycin.  However, advances in understanding essential 
components of mTORC2 signaling has allowed researchers to design experiments to 
understand mTORC2 specific regulation and downstream signaling.  Together, such 
advances and inevitably drug advancement to target mTORC2 aside from mTORC1 will 
further advance the mTOR field of research. 
1.4	   Autophagy	  
 
Autophagy, which literally means, “to eat ones self” is a conserved catabolic 
process where the cell engulfs cytoplasmic components to degrade and in a sense 
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recycle cellular building blocks into essential cellular pathways to maintain cellular 
homeostasis in the context of various stresses such as low energy, low nutrients, 
hypoxia, and pharmacological inhibitors such as mTOR inhibitors.  Autophagy is also 
involved in the regulation of gerosuppression (senecscnece) and molecular aging, 
various aspects of cancer progression and suppression, metabolism, 
neurodegenerative diseases, and development [62-66].   
Autophagy can be thought of as a biological process that is in constant flux.  Its 
initiation is molecular regulated by several complexes, ULK1/ATG/FIP200 and 
Vps34/Beclin1 [67]. Once initiated by cellular cues, sequestration of cellular cargo by a 
double membrane vesicle called the phagophore will elongate to fully encompass all 
cargo in a cellular structure termed the autophagosome.  Cargo may include organelles 
such as mitochondria and endoplasmic reticulum (ER), long lived aggregated proteins, 
lipids, nucleic acids, and also some pathogens [68].  The elongation phase is regulated 
by ATG5/ATG12 and ubiquitin-like protein LC3.  LC3 is lipidated through its conjugation 
to phosphatidylethanolamine (PE) to form LC3-II [69].  This lipidated form of LC3 is 
inserted into the inner and outer autophagosomal membrane as this elongation phase 
leads to closure.  LC3-II is one of the few molecular markers utilized to measure mature 
autophagosome formation [70].  Autophagosomes are termed mature autolysosomes 
once fused to lysosomes.  Fusion with lysosomes results in degradation of sequestered 
cargo by lysosomal enzymes.  Degradative end products of autophagy yield fatty acids, 
amino acids, and nucleotides that are utilized for specific metabolic processes once 
released back into the cytoplasm (Figure 1.5)[68] [68]. 
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Figure 1.5:  Autophagic flux pathway 
Furthermore, completion of the autophagy pathway supports cellular homeostasis 
through provision of essential building blocks for critical cellular and metabolic 
processes such as energy production, lipid formation, and protein synthesis. 
1.4.1	   Autophagy	  and	  cancer	  
 
Recent genetic and molecular understandings have revealed support for 
autophagy as a pro-tumorigenic mechanism [71-74].  This paradigm is thought to be 
through autophagy supporting tumor maintenance in hypoxic regions or areas under 
metabolic stress [75].  However, opposing data also show that autophagy can act as a 
tumor suppressive cellular function  [76-78].  Germline mutations in autophagy 
regulating gene, Becn1 (Beclin1) have been observed ovarian, prostate, and breast 
cancer [79-81].  Additionally, autophagy’s tumor suppressive function may be linked to 
tumors with defects in autophagy as well as apoptosis.  Defects in both of these 
pathways can lead to necrotic cell death and a subsequent inflammatory response, 
inevitably attenuating tumor progression [64].  Importantly, the context at which these 2 
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paradigms establish themselves is unclear and involves complex cross-talk between 
both cellular processes, but may be linked to early stages of transformation [68]. 
Signal transduction pathways, in addition to mutations in specific autophagy 
regulating genes are also implemented in autophagy regulation of cancer development 
[62].  It has now been widely accepted that oncogenic and tumor suppressive pathways 
regulate various metabolic pathways.  In addition to mTOR negatively regulating 
autophagy, AKT and epidermal growth factor receptor (EGFR) have been shown 
phosphorylate Beclin1 to negatively regulate autophagy through an mTOR independent 
mechanism [82,83].  As the field advances and elegant temporal and spatially controlled 
GEMMs are developed, a more clear understanding of ATGs, oncogenes, and tumor 
suppressors and their contribution to autophagy being tumor suppressive or tumor 
promoting will able to be addressed. 
1.5	   ccRCC	  and	  mTOR	  signaling	  
 
Previous studies and more recent TCGA (28% of core set samples) analyses has 
revealed alterations is various components responsible for increased mTOR signaling in 
patient ccRCC tumors [31,84].  Abnormal augmentation of oncogenic signaling 
pathways suggests possible addiction to the altered pathway.  This “oncogenic 
addiction” reveals possible therapeutic potential and supports why patients receiving 
temsirolimus or everolimus for advanced RCC show progression free and overall 
survival benefit.  However, not all patients respond and those that do present sensitivity 
eventually become refractory to treatment.   
Treatment of ccRCC cell lines with rapamycin decreases HIF1α expression and 
modestly HIF2α expression, revealing distinct sensitivity of HIF1α and HIF2α to 
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rapamycin [85,86].  Furthermore, Thomas and colleagues demonstrated RCC cells 
harboring loss of pVHL show sensitivity to derivatives of rapamycin, and the efficacy 
observed may be due to attenuation of translational regulation of HIF by mTOR [86].  
Additionally, Toschi and colleagues used RNAi to dissect out the contribution of 
mTORC1 and mTORC2 regulation of HIF1α and HIF2α.  Their data revealed that RNAi 
directed to mTOR or Rictor+Raptor positively regulates HIF1α, while mTORC2 inhibition 
by Rictor KD alone is capable of inhibiting HIF2α [85].  Additionally, TCGA data 
analyzing ccRCC tumor samples reported mutations in mTOR and genomic alterations 
associated with activation of the PI3K/mTOR signaling cascade [31]. 
Such strategies as those above have revealed some insight into mTOR signaling 
amplification and subsequent regulation of relative oncogenic and tumor suppressive 
pathways in ccRCC.  These observations shed light into why subpopulations of patients 
may respond better than others to current therapeutic options for inhibiting mTOR.  
Lastly, development of therapeutic inhibitors (i.e. catalytic mTOR inhibitors) capable of 
indirectly inhibiting not only HIF1α but also HIF2α may show increased efficacy against 
tumor supporting pathways in ccRCC [87,88]. 
1.6.1	   Pharmacologic	  targeting	  of	  mTOR	  in	  ccRCC	  
 
Rapamycin is a macrolide constructed by Streptomyces Hygroscopicus bacteria 
with high specificity for inhibiting mTORC1 [89] and recent evidence for detecting 
aberrant mTOR signaling in a variety of cancers has yielded additional rapamycin 
derivatives (i.e. temsirolimus and everolimus) harboring more acceptable 
pharmacodynamics to be used in pre-clinical and clinical studies [44,90].  Specifically, 
intravenous rapamycin derivative, temsirolimus, was approved by the FDA in 2007 for 
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the treatment of advanced stage renal cell carcinoma [91], and in 2009  everolimus, an 
orally available analogue of rapamycin, was approved as a second therapeutic option 
for patients who’s diseased progressed after tyrosine kinase inhibitor (TKI) treatment.  
However, patients typically acquire resistance to allosteric mTOR inhibitors resulting in 
progression of their disease [92].  This common clinical observation warrants new 
efforts to understand potential compensatory survival mechanisms capable of being 
targeted to improve clinical efficacy. 
Advances in drug development has resulted in an array of various mTOR inhibitors 
capable of inhibiting the kinase activity of mTOR through binding and disruption of the 
interaction of ATP within the catalytic domain [59].  Disruption of mTOR kinase activity 
in RCC cells inhibits both mTORC1 and mTORC2 signaling cascades [93-96].  
Specifically, catalytic mTOR inhibitors are capable of not only inhibiting S6K but also 
4E-BP1 effectors downstream of mTORC1.  Respective to mTORC2 inhibition, 
treatment with catalytic mTOR inhibitors inhibits AKT compensatory mTORC2 survival 
signaling induced in the context of allosteric mTOR inhibition.  Secondary, to direct 
inhibition of mTORC1 and mTORC2, catalytic mTOR inhibitors are capable of 
decreasing HIF2α, an essential component shown to regulate tumor growth and 
progression and also poor prognosis factor in VHL deficient RCC cells and ccRCC 
patients [20,94].  Functionally, catalytic mTOR inhibitors are better at decreasing cell 
viability and tumor growth than allosteric mTOR inhibitors in the context of RCC [94,96].  
Clinically, cases have been reported for patients that had above average response rates 
receiving a derivative of rapamycin after failing VEGF targeted therapy.  Deep 
sequencing for genomic alterations within these patients’ primary tumor and metastatic 
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sites revealed alterations supporting for activation of the mTOR pathway, illustrating 
why these select patients responded well to a therapeutic targeting mTOR [97]. 
Although rapaymcin derivatives have shown to be promising in treating advanced 
RCC [91,98] there can be activation of compensatory survival pathways [94,95].  For 
instance, compensatory activation of mTORC2 by rapamycin has been demonstrated in 
a variety of cancer types [99] and may also serve as a survival mechanism in RCC 
[100].  Although catalytic mTOR inhibitors have been shown to improve efficacy over 
allosteric mTOR inhibitors in RCC [94,96] there too are consequences of such inhibition.  
For instance, rapamycin and catalytic mTOR inhibitors have been shown to induce 
mitogen activated protein kinase (MAPK/ERK) signaling and autophagy in cancer cells 
[101-106].  Furthermore, treatment with catalytic inhibitors may increase activity of these 
pathways more than rapamycin [107,108].  Deciphering the regulation of mTORC1 and 
mTORC2 on these compensatory pathways in RCC has yet to be investigated more 
thoroughly and will be the main focus of Chapter 2 of this document.  
1.6.2	   Autophagy	  induction	  through	  mTOR	  inhibition	  
 
It is well understood that mTOR negatively regulates autophagy, and it has been 
demonstrated that treatment with mTOR inhibitors is capable of inducing autophagy in 
cancer cells [93,103,109-112].  Furthermore, several groups have revealed that catalytic 
mTOR inhibitors appear to augment autophagic flux more than allosteric mTOR 
inhibitors [107,108].  The mechanism behind these observations is not well understood, 
however several groups have shown decreased expression of pULK1S757 with catalytic 
mTOR inhibitors and minimal to no reduction with rapamycin in cancer cells [107,112].  
Phosphorylation of ULK1 at Ser757 by mTOR correlates with autophagy inhibition 
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[48,49,113].  Furthermore, only RNAi targeting mTOR was capable of decreasing 
expression of pULK1S757 in ovarian cancer cells, again suggesting that direct inhibition 
of mTOR may be the reason for the increased autophagy observed with catalytic mTOR 
inhibitors when compared to allosteric mTOR inhibitors [107].   
Additionally, activation of autophagy via mTOR inhibition has been shown to 
function as a compensatory survival mechanism that can be targeted to enhance the 
efficacy of mTOR inhibition on cancer cell proliferation and survival [93,103,111,114].  
Interestingly, in glioblastoma [103], it appears that inhibition of autophagy with 
rapamycin does not yield the same effect of increasing apoptosis as catalytic 
PI3K/mTOR inhibition and autophagy inhibition.  However, in RCC cells it appears that 
a derivative of rapamycin plus autophagy inhibition can induce necroptosis as a 
programmed cell-death signal [109].  Understanding the direct role of increasing 
autophagic flux by differing types of mTOR inhibitors may require a better 
understanding of not only mTORC1, but also mTORC2’s regulation of autophagy.  
Chapter 3 will investigate autophagic flux response to allosteric and catalytic mTOR 
inhibition to determine if autophagic induction is indeed targetable in RCC cells treated 
with various mTOR inhibitors. 
1.6.3	   mTOR	  inhibition	  and	  MEK/MAPK	  signaling	  crosstalk	  
 
It is well understood that oncogenic and tumor suppressive signal transduction 
pathways are not linear, but exhibit complex cross-talk between pathways [115].  This 
paradigm has been clearly observed within the PI3K-mTOR and Ras-ERK signaling 
pathways [115].  A hallmark of cancer is its ability to acquire resistance to targetable 
therapies resulting in a reduction of tumor responsiveness.  PI3K-mTOR pathway 
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activation was found in 28% of the TCGA ccRCC samples and has been linked to 
several noted genetic lesions in a cohort of ccRCC patient tumors [31] supporting 
possible addiction to this pathway and respectable therapeutic targets.  Unfortunately, 
patients with advanced RCC treated with mTOR inhibitors typically result in cytostatic 
responses followed by an acquired resistance to the current therapeutic regimen.  
Observations such as these imply the importance to understand potential resistance 
mechanisms to generate high-order combinatorial approaches prolong survival. 
Specifically, compensatory targetable MAPK survival and proliferation signals 
have been observed in the context of mTOR inhibition [101,102,105,106,116].  
Interestingly, it has been noted that allosteric and catalytic mTOR inhibitors have 
varying effects on MAPK signaling induction [102], but the molecular mechanisms 
deciphering the sensitivity to this induction are not well understood.  A mTORC1-MAPK 
feedback loop dependent upon PI3K activation has been described through studies with 
rapamycin as a potential mechanism for the compensatory MAPK activation in the 
presence of mTOR inhibition [101].   Additionally, activation of p90RSK and the 
subsequent inhibition of downstream pro-apoptotic effectors are also plausible 
mechanisms of resistance to allosteric mTOR inhibition [116].  The importance of mTOR 
inhibition and compensatory modulation of MAPK apoptotic signaling pathways in RCC 
has not been established.  Therefore, understanding the genetic and molecular 
underpinnings of MAPK compensatory survival and proliferation signals will aid 
clinicians in selecting plausible therapeutic combinations in conjunction with current 
FDA approved rapamycin derivatives and possible future catalytic mTOR inhibitors 
when treating advanced RCC. 
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CHAPTER 2 
MTOR INHIBITION INDUCES COMPENSATORY, THERAPEUTICALLY 
TARGETABLE MEK ACTIVATION IN RENAL CELL CARCINOMA2 
2.1	   Overview	  
 
 
Rapamycin derivatives allosterically targeting mTOR are currently approved by 
the FDA to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of 
mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to 
investigate the relative efficacy of allosteric versus catalytic mTOR inhibition, evaluate 
the crosstalk between the mTOR and MEK/ERK pathways, as well as the therapeutic 
potential of dual mTOR and MEK inhibition in RCC.  Pharmacologic (rapamycin and 
BEZ235) and genetic manipulation of the mTOR pathway were evaluated by in vitro 
assays as monotherapy as well as in combination with MEK inhibition (GSK1120212).  
Catalytic mTOR inhibition with BEZ235 decreased proliferation and increased apoptosis 
better than allosteric mTOR inhibition with rapamycin.  While mTOR inhibition 
upregulated MEK/ERK signaling, concurrent inhibition of both pathways had enhanced 
therapeutic efficacy. Finally, primary RCC tumors could be classified into subgroups [(I) 
MEK activated, (II) Dual MEK and mTOR activated, (III) Not activated, and (IV) mTOR 
activated] based on their relative activation of the PI3K/mTOR and MEK pathways. 
                                            
2Chapter 2 is from Sean T. Bailey, Bing Zhou, Jeffrey S. Damrauer, Bhavani Krishnan, Harper L. Wilson, 
Aleisha M. Smith, Mingqing Li, Jen Jen Yeh, and William Y. Kim.  mTOR inhibition induces compensatory, 
therapeutically, targetable MEK activation in renal cell carcinoma.  PLoS 2014 (in press) 
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Patients with mTOR only activated tumors had the worst prognosis. In summary, dual 
targeting of the mTOR and MEK pathways in RCC can enhance therapeutic efficacy 
and primary RCC can be subclassified based on their relative levels of mTOR and MEK 
activation with potential therapeutic implications.  
2.2	   Introduction	  
 
Recent statistics suggest that there are predicted to be roughly 65,000 new 
cases and 14,000 deaths in 2013 from renal cell carcinoma (RCC) [1,3]. Clear cell renal 
cell carcinoma (ccRCC) is the most common histologic subtype of RCC and the vast 
majority of sporadic ccRCC have inactivation of the von Hippel-Lindau tumor 
suppressor protein (pVHL).  Patients with VHL disease have inherited mutations of VHL 
and renal cyst and/or tumors develop when these individuals undergo somatic 
inactivation or loss of the remaining wild-type VHL allele [6,117].  pVHL’s most well 
understood function is to negatively regulate the hypoxia-inducible factor alpha (HIFα) 
family of transcription factors (HIF1α, HIF2α, HIF3α) in an oxygen dependent manner 
via its E3 ubiquitin ligase activity [12,89].  Importantly, pVHL’s tumor suppressor 
function is dependent upon the downregulation of HIFα subunits and in particular HIF2α 
[20-22]. 
Stabilization of HIFα, either as a consequence of hypoxia or pVHL inactivation 
leads to transcriptional activation of numerous genes associated with adaptation to a 
hypoxic environment as well as a favorable tumor microenvironment [3,89,118].  The 
development of FDA approved therapies for combating ccRCC has been heavily 
influenced by an understanding of the molecular underpinnings of VHL disease.  
Specifically, small-molecule tyrosine kinase inhibitors (e.g. sunitinib and pazopanib) 
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have been developed to inhibit vascular endothelial growth factor receptor (VEGFR) 
and platelet derived growth factor receptor (PDGFR) [117,119].  Additionally, 
temsirolimus and everolimus, derivatives of rapamycin, are approved to treat advanced 
RCC [89].  While significant tumor responses are seen in the setting of VEGFR 
inhibition they are much less common upon mTOR inhibition suggesting potential 
compensatory survival and proliferative mechanisms that can be co-targeted [91,98].   
Rapamycin and its derivatives are allosteric inhibitors of the serine/threonine 
kinase mechanistic target of rapamycin (mTOR) that require rapamycin’s association 
with cytosolic protein, FKBP12 [35,89].  mTOR integrates extracellular growth signals 
with cellular responses such as proliferation, autophagy, metabolism, cell growth and 
survival [44].  The mTOR protein kinase interacts with several proteins to form two 
distinct complexes, mTORC1 and mTORC2.  Both mTORC1 and mTORC2 are 
composed of the common subunits: DEP domain containing mTOR-interacting protein 
(DEPTOR), mammalian lethal with sec-13 protein 8 (mLST8), and tti1/tel2 complex.  
However, they differ in composition by several additional proteins.  Regulatory-
associated protein of mammalian target of rapamycin (Raptor) and proline-rich AKT 
substrate 40 KDa (PRAS40) are distinct to the mTORC1 signaling complex while 
rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated map 
kinase-interacting protein1 (mSin1), and protein observed with Rictor 1 and 2 (protor1/2) 
are associated with mTORC2 [36].  Notably, the mTORC2 complex is thought to be 
relatively insensitive to rapamycin [38].  Furthermore, treatment with rapamycin and it’s 
derivatives causes a release of negative feedback on the PI3K/AKT signaling pathway 
[45,99]. Therefore, the inability of rapamycin to inhibit all signaling nodes of mTOR has 
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warranted efforts to develop catalytic mTOR inhibitors capable of perturbing mTOR’s 
kinase activity and therefore blocking both mTORC1 and mTORC2 complexes [90].   
 However, recent reports have demonstrated that inhibitors of mTOR are capable 
of increasing MEK/ERK activation and its associated proliferation and survival signaling 
in cancer cells [101,105,106,120-123].  Interestingly, several groups have observed that 
catalytic mTOR inhibition increases compensatory MEK/ERK signaling greater than 
allosteric mTOR inhibition [102,105].  This particular observation has resulted in pre-
clinical and clinical studies utilizing mTOR inhibition in combination with MEK inhibition 
for treating several cancer types [106,124-126].  
Here, we investigate, through both a pharmacologic and genetic approach, the 
compensatory proliferation and survival pathways observed in the context of allosteric 
and catalytic mTOR inhibition. The studies conducted here support that catalytic mTOR 
inhibition may be better than allosteric inhibition at restraining cellular proliferation and 
increasing apoptosis.  However, we also observe that catalytic mTOR inhibition is more 
robust at initiating compensatory MEK/ERK signaling in RCC.  We address these 
compensatory cross-talk pathways through pharmacologic inhibition and demonstrate 
that the selected combinatorial approaches reveal an enhanced effect at attenuating 
cellular proliferation and augmenting the apoptotic response in RCC cells.  
2.3	   Results	  
2.3.1	   Novel	  renal	  cell	  carcinoma	  cell	  lines	  lack	  VHL	  and	  overexpress	  HIFα 	  
 
In order to aid our studies, we generated two novel ccRCC cell lines (hereafter 
called UNC-R1 and UNC-R2) from primary patient-derived xenografts (PDX).  H&E 
staining of a portion of the PDX tumor demonstrated clear cell histology (Figure 2.1A).  
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Cell morphology of the cell lines remained consistent over time.  To characterize the 
novel cell lines VHL, HIF1α, and HIF2α expression of the cell lines were determined by 
western blot (Figure 2.1B).  RCC4 2-1 (VHL null) and RCC4 3-14 (VHL wt) were used 
as controls to validate current findings.  Both the UNC-R1 and the UNC-R2 cell lines 
lacked appreciable expression of VHL. While both cells lines expressed HIF2α, only 
UNC-R1 expressed HIF1α (Figure 2.1B), suggesting that UNC-R2 cells have lost HIF1α 
expression as is seen in a proportion of ccRCC cell lines and primary tumors and 
consistent with the notion that HIF1α is potentially a tumor suppressor gene [25]. 
 
Figure 2.1:  Novel renal cell carcinoma cell lines lack VHL and overexpress HIF 
(A) Photomicrographs of H&E stains (left panels) and bright field images (right panels) 
of UNC-R1 and UNC-R2 PDX derived cell lines. (B) Whole cell extracts from UNC-R1 
and UNC-R2s were immunoblotted with the indicated antibodies.  RCC4 2-1 (VHL null) 
and RCC4 3-14 (VHL positive) were included as controls. 
 
2.3.2	   Catalytic	  mTOR	  inhibitors	  block	  mTORC1	  signaling	  more	  fully	  than	  allosteric	  mTOR	  
inhibition	  
 
  
44 
Previous studies have demonstrated that the dual catalytic PI3K/mTOR inhibitor, 
BEZ235, inhibits mTORC1 signaling better than allosteric mTOR inhibition with 
rapamycin or other rapalogs [94,104,111,127,128].  We wished to see whether these 
results could be replicated in our hands.  Dose titrations of rapamycin and BEZ235 in a 
panel of human RCC cell lines showed that 200nM and 1uM respectively were required 
to inhibit mTORC1 and/or mTORC2 signaling (Supplemental Figure 2.1A and 2.1B).  
These doses of rapamycin and BEZ235 were therefore used to treat a panel of RCC 
cell lines.  As expected, while both compounds inhibited the phosphorylation of S6, only 
BEZ235 inhibited phosphorylation of 4EBP1 and AKT Ser 473 (Figure 2.2).  Moreover, 
as previously described, allosteric mTOR inhibition with rapamycin resulted in increased 
pAKTS473 expression in 786-0, RCC4, and UNC-R2 cells (Figure 2.2) presumably as a 
result of release of S6K and IRS1 dependent negative feedback inhibition of PI3K/AKT 
signaling [99]. 
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Figure 2.2:  Catalytic mTOR inhibitors block mTORC1 signaling more fully than 
allosteric mTOR inhibition.  The indicated cell lines were treated with the allosteric 
and catalytic mTOR inhibitors (rapamycin and BEZ235 respectively) at the indicated 
concentrations for 24 hrs.  Whole cell extracts were then immunoblotted with the 
indicated antibodies. 
2.3.3	   Catalytic	  mTOR	  inhibition	  is	  superior	  to	  allosteric	  mTOR	  inhibition	  at	  attenuating	  
cellular	  proliferation	  and	  inducing	  apoptosis	  
 
Previous groups have demonstrated that BEZ235 is better than rapamycin at 
decreasing cellular proliferation in RCC [94].  We utilized CellTiter-Glo® to measure 
alterations in cellular viability over the course of 4 days.  Consistent with previous 
results, our data show that BEZ235 inhibits cellular proliferation better than rapamycin 
(Figure 2.3A, Supplemental Figure 2.2).  Interestingly, both primary cell lines (UNC-R1 
and UNC-R2), but especially UNC-R2, seemed exquisitely sensitive to BEZ235 as 
evidenced by significantly fewer cells present at day 4 than to day 0 (Figure 2.3A).    
 While they prolong overall survival, allosteric mTOR inhibitors such as 
everolimus and temsirolimus have displayed little cytotoxic effects in patients (i.e. they 
lead to few objective responses) [91].  Catalytic mTOR inhibitors have shown increased 
efficacy in generating an apoptotic response in preclinical studies, likely as a result of 
decreasing AKT mediated survival signals [111,127].  Treatment of RCC4, 786-0, and 
RCC10 cells with BEZ235 resulted in increased apoptosis as evidenced by the 
increased expression of the apoptotic marker, cleaved PARP (poly ADP ribose 
polymerase) (Figure 2.3B).  Moreover, BEZ235 also increased expression of another 
apoptotic marker, cleaved-caspase 3, in RCC4 and RCC10 cells (Supplemental Figure 
2.3).  Interestingly, 786-0 and RCC4 cells showed a decrease in cleaved-PARP 
expression when treated with rapamycin (Figure 2.3B) likely as a consequence of the 
increased survival signaling from AKT (Figure 2.2).  Additionally, assessment of 
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apoptosis by flow cytometry (Annexin V+/PI- fraction) also showed that RCC cells 
treated with BEZ235 had increased apoptosis respective to rapamycin treated cells 
(Figure 2.3C).  Therefore, catalytic mTOR inhibition is superior to allosteric mTOR 
inhibition at attenuating cellular proliferation and inducing apoptosis. 
 
Figure 2.3:  Catalytic mTOR inhibition attenuates proliferation and induces 
apoptosis better than allosteric mTOR inhibition.  (A) The indicated cell lines were 
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assessed for viability on the indicated days using CellTiter-Glo®.  Statistical significance 
was determined by comparing rapamycin and BEZ235 treated groups.  (B) The 
indicated cell lines were treated with rapamycin and BEZ235 for 48 hours and 
immunoblotted with the indicated antibodies.  (C) The indicated cell lines were treated 
with rapamycin and BEZ235 for 48 hours and assessed for apoptosis by flow cytometry 
analysis of the Annexin V+/PI – fraction.  (D) 786-0 cells were stably infected with 
shRNAs targeting Raptor (mTORC1) or Rictor (mTORC2) and confirmed for knock-
down by western blot.  (E) Whole cell extracts from 786-0 shNS, shRaptor, and shRictor 
cells were immunoblotted with the indicated antibodies. 
2.3.4	   mTORC2	  activity	  negatively	  regulates	  the	  apoptotic	  response	  through	  phosphorylation	  
of	  AKT	  
We wanted to determine whether the enhanced apoptosis seen with BEZ235 
treatment (relative to rapamycin) was due to its ability to inhibit mTORC2 and 
subsequent downregulation of AKT dependent survival signaling.  Since there are no 
pharmacologic inhibitors capable of specifically inhibiting mTORC2, we silenced Rictor 
expression, which is required for mTORC2 activity (Figure 2.3D).  Knock-down of Rictor 
significantly decreased expression of pAKTS473 and pAKTT308 as well as increased 
cleaved-PARP (Figure 2.3E).  In contrast, knock-down of Raptor, which is required for 
mTORC1 activity, appeared to slightly decrease cleaved-PARP expression while mildly 
increasing pAKTS473 or pAKTT308 expression.  These results support the notion that the 
increased apoptosis seen with BEZ235 relative to rapamycin treatment are a result of 
BEZ235’s inhibition of mTORC2 activity. 
2.3.5	   mTOR	  inhibition	  induces	  compensatory	  activation	  of	  MEK/ERK	  signaling	  
 
Recent reports have demonstrated cross-talk between the mTOR and MEK/ERK 
signaling pathways [115].  To see whether this interplay was present in the context of 
RCC we examined the response of ERK and a canonical ERK substrate, p90RSK, to 
rapamycin or BEZ235.  Both pERK and p-p90RSK were induced by allosteric and 
catalytic mTOR inhibition (Figure 2.4A). While there was a sense that BEZ235 treatment 
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resulted in a slightly larger increase in p-p90RSK in a subset of the cell lines, this was 
not accompanied by the same amount of induction of pERK.  This could reflect 
enhanced ERK activity that is not appreciable by pERK western blotting or mTOR 
inhibition induced p-p90RSK that is ERK independent.  However, ERK is the only 
described kinase to phosphorylate p90RSK on the S380 site [129].  Overall, these 
results suggest that mTOR inhibition of RCC cells upregulates MEK/ERK signaling and 
that catalytic mTOR inhibition may do so in a more robust manner than allosteric 
inhibition. 
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Figure 2.4:  Combined mTOR and MEK inhibition attenuates cellular proliferation 
and increases the apoptotic response.  (A) The indicated cells were treated for 24 
hrs. with rapamycin or BEZ235 and immunoblotted with the indicated antibodies. (B) 
786-0 and RCC4 cells were treated increasing doses of GSK212 for 24 hrs. and 
immunoblotted with the indicated antibodies.  (C) 786-0 and RCC4 cells were treated for 
24 hrs with rapamycin and BEZ235 in the presence of Edu.  Edu incorporation was 
assessed by flow cytometry.  (D) 786-0 and RCC4 cells were treated with the indicated 
compounds for 24 hrs. Whole cell extracts were immunoblotted for the cell cycle related 
proteins indicated.  (E) 786-0 and RCC4 cells were treated with indicated drugs and 
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assessed for viability on day 4 using CellTiter-Glo® 4.  (F) 786-0 and RCC4 cells were 
plated, allowed to attach, and treated with the indicated drug(s).  Photographs of wells 
containing 786-0 (day 11) and RCC4 (day 17) cells fixed with 4% PFA and stained with 
0.1% crystal violet.  (G) 786-0 and RCC4 cells were treated with the indicated 
compounds for 24 hrs.  Whole cell extracts were immunoblotted with the indicated 
antibodies. 
2.3.6	   Combination	  of	  mTOR	  and	  MEK	  inhibition	  attenuates	  cellular	  proliferation	  and	  
increases	  the	  apoptotic	  response	  
 
The observation of increased MEK/ERK signaling in the context of mTOR 
inhibition led us to hypothesize that attenuation of this compensatory signal may 
decrease cellular proliferation and induce apoptosis.  We saw that 10nM of the MEK 
inhibitor GSK1120212 (hereafter called GSK212) was sufficient to fully inhibit MEK 
activity as assessed by pERK T202/Y204 in several RCC cell lines (Figure 2.4B).  
Treatment of RCC cell lines with rapamycin or BEZ235 led to a decrease in the 
percentage of cells in S phase as determined by Edu incorporation (Figure 2.4C).  The 
combination of MEK inhibition with mTOR inhibition led to a potent reduction in S phase 
fraction, particularly when GSK212 was combined with BEZ235.  As expected, MEK 
inhibition led to hypophosphorylation of Rb as well as downregulation of cyclin B1 and 
cyclin D1 consistent with increased cell cycle arrest.  However, the addition of mTOR 
inhibition did not further change levels of these proteins (Figure 2.4D).   
 Despite the fact that the combination of BEZ235 and GSK212 potently inhibited 
cell cycle progression, there did not appear to be an additive effect on proliferation or 
colony formation (Figure 2.4E and 2.4F).  We hypothesized that this lack of additivity 
was secondary to the high level of inhibition of proliferation and colony formation by 1 
µM BEZ235 alone.  Therefore, we determined the IC50 for BEZ235 in several RCC cell 
lines (Supplemental Figure 4A), confirmed that the determined IC50 was capable of 
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inducing activation of MEK/ERK signaling (Supplemental Figure 2.4B), and examined its 
effects on proliferation on colony formation.  The combination of 2 nM of BEZ235 with 
GSK212 resulted in significant decreases in proliferation (Supplemental Figure 2.5A) 
and colony formation (Supplemental Figure 2.5B) over either single agent alone.  
Furthermore, the combination of mTOR inhibition with MEK inhibition augmented the 
apoptotic response as evidence of increased C-PARP expression in 786-0 and RCC4 
cells treated with the combination (Figure 2.4G).  Together, these data support the 
notion that combined mTOR and MEK inhibition might be an effective therapy in RCC 
2.3.7	   Subclasses	  of	  RCC	  can	  be	  defined	  by	  MEK	  and	  mTOR	  pathway	  activation	  
 
To assess the potential relevance of MEK and /or mTOR inhibition in ccRCC we 
examined reverse phase protein array data (RPPA) from the TCGA clear cell kidney 
cancer project (KIRC) to determine the relative activation state of these pathways in 
human RCC [31].  Reverse phase protein arrays are a highly validated technique 
allowing the assessment of protein expression across hundreds of proteins 
simultaneously and because of the multiplatform nature of the TCGA allows for 
correlations to other genomic aspects of a tumor.  To this end, TCGA KIRC tumors were 
hierarchically clustered using log2 transformed, median centered, RPPA expression 
data of canonical phosphoproteins that represent activation of the MEK (pERKT202/Y204), 
PI3K (pAktT308), mTORC1 (p4E-BP1T70, p4E-BP1T37, pS6S235/236, pS6S240/244, 
p70S6KT389) and mTORC2 (pAktS473) pathways (Figure 2.5A). There were 4 well-
defined clusters of tumors that appeared to represent differential patterns of MEK and 
mTOR activation: 1) MEK activation [I: black].  2) dual MEK and mTOR activation [II: 
red].  3) no activation [III: green].  and 4) mTOR activation [IV: blue]. These subgroups 
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could be also visualized using a plot that graphed the relative expression of the 
canonical markers of MEK activation (pERKT202/Y204) and mTORC1 activation (pS6S235) 
(Figure 2.5B).   
Finally, we wanted to see if our MEK/mTOR subgroups held prognostic value 
and thus assessed their patterns of overall survival.  We found that patients with mTOR 
activated tumors (IV: blue) had the worse overall survival while patients with high MEK 
activation, regardless of mTOR status, had the best survival (I: black and II: red) (Figure 
2.5C). Patients with RCC tumors without activation (III: green) had an intermediate 
overall survival.  Therefore, subclasses of RCC tumors can be identified based on their 
relative activation of the MEK and mTOR pathways and the subclasses correlate with 
prognosis. 
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Figure 2.5:  Subclasses of RCC can be defined by MEK and mTOR pathway 
activation.  (A) TCGA KIRC RPPA data was log2 transformed, median centered.  
Tumors were then hierarchically clustered and the indicated subgroups were 
determined based on expression patterns of the indicated phosphoproteins. Mutational 
data for mTOR pathway related genes were annotated in the upper tracks.  (B) Scatter 
plot of TCGA KIRC tumors based on expression of pS6 and pERK.  Each dot indicates 
a tumor.  The MEK-PI3K/mTOR subclasses defined in (A) are indicated by color.  (C) 
Patients harboring tumors within each MEK-PI3K/mTOR subclass were evaluated for 
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differences in overall survival by the Log Rank test and shown as a Kaplan-Meier plot of 
overall survival. 
2.4	   Discussion	  
 
Our studies investigate the relative efficacy of allosteric versus catalytic mTOR 
inhibition in RCC through both pharmacologic and genetic approaches.  We show that 
as monotherapy, catalytic mTOR inhibition is better at decreasing cellular proliferation 
and inducing apoptosis than allosteric mTOR inhibition consistent with previous studies 
in RCC [94].  However, despite these potentially therapeutically beneficial 
characteristics, we show that catalytic mTOR inhibition also induces a more robust 
induction of compensatory MEK/ERK signaling.  Nonetheless, the compensatory 
upregulation in MEK/ERK signaling can be targeted with small molecule kinase 
inhibition, resulting in enhanced therapeutic efficacy.  Finally, we demonstrate that 
primary RCC tumors can be classified based on their relative activation of the MEK and 
mTOR pathways and that these different MEK/mTOR subtypes are associated with 
differences in overall survival. 
Dual inhibition of the MEK and PI3K/mTOR pathways has shown preclinical 
promise as a therapeutic strategy in a variety of tumors [106,122-124,130-132] and has 
entered into phase 1 trials in humans [125].  Inhibition of the MEK/ERK and PI3K/mTOR 
pathways is a rational strategy based on the extensive crosstalk between the two 
pathways and the well documented compensatory signaling that occurs in the face of 
MEK or mTOR inhibition [115].  Nonetheless, neither dual inhibition nor the 
compensatory cross-talk between the MEK and PI3K/mTOR pathways has been 
explored specifically in the context of RCC where it is highly clinically relevant given the 
approval of the allosteric mTOR inhibitors everolimus and temsirolimus for patients with 
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advanced disease [91].  Therefore, our studies are the first to investigate this crosstalk 
and its potential clinical relevance in RCC.  
Our studies showed that mTOR inhibition in RCC cell lines resulted in increased 
MAPK signaling in the context of both allosteric and catalytic mTOR inhibition (Figure 
4A).  Moreover, we noted that catalytic mTOR inhibition enhanced ERK 
phosphorylation, as well as phosphorylation of the ERK substrate, p90RSK more than 
robustly than allosteric mTOR inhibition (Figure 4A and G).  Precisely how mTOR 
inhibition in RCC results in increased MEK/ERK signaling remains to be determined.  
Further investigation into this is warranted but overall our results are consistent with the 
notion that kinase inhibition results in upregulation of compensatory pathways and 
kinome reprogramming [133]. 
Examination of the RPPA data from the TCGA-Kidney Renal Clear Cell 
Carcinomas (KIRC) project allowed us to assess the possibility that RCC could be 
divided into subclasses based on the relative activation of the MEK and mTOR 
pathways as well as evaluate their potential therapeutic significance [31].  We have 
named these groups, MEK activated, mTOR activated, dual MEK and mTOR activated, 
and not activated.  We propose that rational targeted therapy for the MEK/mTOR 
subgroups might include: MEK activated – MEK inhibitor, mTOR activated – allosteric or 
catalytic mTOR inhibitor, dual MEK and mTOR activated – combination MEK and 
mTOR inhibitor, and not activated – VEGFR tyrosine kinase inhibitor.    
Patients with mTOR activated tumors had the worse overall survival relative to 
the other subgroups and are also the only subgroup that would be predicted to benefit 
from single agent, allosteric mTOR inhibition.  Intriguingly, temsirolimus has been 
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shown in a phase III randomized trial to prolong the overall survival of patients with 
“poor prognosis” as defined by the MSKCC criteria [91,134].  While we cannot be sure 
that our mTOR activated group corresponds to the “poor prognosis” patients defined by 
the MSKCC criteria, if they do correlate, our data provides a biological explanation for 
this interesting clinical observation. 
In summary, our studies demonstrate that catalytic mTOR inhibition is more 
effective than allosteric, but that catalytic mTOR inhibition appears to more robustly 
induce alternative compensatory pathways (i.e. MEK/ERK).  Nonetheless, 
compensatory upregulation of MEK/ERK signaling can be co-targeted with enhanced 
therapeutic effectiveness.  Furthermore, we describe distinct subclasses of RCC that 
can be defined by the activation of the MEK and mTOR pathways, have clinically 
distinct prognosis, and would be predicted to have differential responses to MEK and 
mTOR kinase inhibition.  In aggregate, our data suggests that catalytic mTOR inhibition 
should be investigated in RCC and that the compensatory upregulation of MEK/ERK 
signaling may actually be a potential synthetic vulnerability in RCC 
2.5	   Materials	  and	  methods	  
 
Patient-derived xenograft cell isolation 
Xenografts were excised and washed in a solution of Pen-Strep, 1XPBS solution 
(1:1).  In sterile conditions, xenografts were then cut into small 2x2mm fragments and 
dissociated in gentleMACSTM C-Tube (Miltenyi Biotec) using the gentleMACs 
Dissociator (program:  m_imp Tumor_02) in 5 mL of complete DMEM.  Then 100 µL of 
collagenase D/dispase II (Roche:  40 mg/mL) was added to the tumor fragments and 
continuously inverted for 30 min at 37°C.  Fragments were then subjected to another 
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round of dissociation using the gentleMACSTM Dissociator (program:  m_imp 
Tumor_03).  5 mL of protein extraction buffer (PEB:  buffer 0.5% FBS, 2mM EDTA in 
PBS) was added to the dissociated fragments and resuspended by pipetting.  The cell 
suspension was transferred to a 50 mL conical tube through a 40 µm nylon mesh sterile 
cell strainer (Fisher).  An additional 20 mL of PEB buffer was added to the cell 
suspension and it was then centrifuged at 300 g’s for 5 min.  Supernatant was removed 
and cell pellet was resuspended in 6 mL of complete DMEM and placed in a 6 cm 
sterile cell culture plate. De-identified tumor tissue was obtained from the University of 
North Carolina Institutional Review Board (IRB) approved tissue procurement facility 
after University of North Carolina IRB approval.  The animal work was approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
 
Cell lines and culture conditions 
RCC10, 786-0, RCC4, UNC-R1, UNC-R2 were cultured in complete DMEM 
(CORNING-Cellgro #10-013-CV) supplemented with 10%FBS, 1X Penn/Strep at 37°C, 
5% CO2, 21% O2.  786-0 cells were obtained from ATCC.  RCC4 cells were obtained 
from Dr. Kimryn Rathmell [11] and RCC10 cells were obtained from Dr. Michael Ohh 
[135].  RCC tumor tissue from de-identified patients were obtained from the University 
of North Carolina Institutional Review Board (IRB) approved tissue procurement facility 
after IRB approval. UNC-R1 and UNC-R2 cell lines were generated as above from the 
renal patient derived xenografts.  BEZ235 (Center for Integrative Chemical Biology & 
Drug Discovery, UNC Eshelman School of Pharmacy), GSK1120212 
(GlaxoSmithKline), Rapamycin (LC Laboratories) were dissolved in DMSO. 
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Immunoblot conditions 
Cells were lysed in RIPA buffer complemented with Set I and Set II phosphatase 
inhibitors at 1X (Calbiochem), and protease inhibitors at 1X (Roche).  Whole cell lysate 
concentration was determined with Bio-Rad Protein Assay Dye Reagent Concentrate 
(Bio-Rad).  Proteins were resolved on SDS-PAGE gels and electrotransferred to 
nitrocellulose membranes, 0.2 µm (Bio-Rad).  Primary antibodies pS6S235/236, S6, 
pAKTS473, AKT, p4E-BP1T37/46, 4E-BP1, Cleaved PARP, pAktT308, p62, Rictor, Raptor, 
HIF-1α, HIF-2α, pERK1/2T202/Y204 (mouse), ERK, p-p90RSKS380, RSK1/2/3, pBADS112, 
pBADS136, pEGFRY1068, cleaved-caspase3 were from Cell Signaling Technologies®.  
VHL (Santa Cruz #FL-181). mTOR primary antibody was from Millipore.  Primary 
antibody dilutions were to manufactures’ specifications (See Supplemental Table 1). 
Tubulin (Sigma #T5168), KU-80 (GeneTex #GTX70485) and Actin-HRP (Santa Cruz 
#C-11) primary antibodies served as loading controls (LC) where noted.  Secondary 
anti-Rabbit and ant-mouse antibodies were from (Fisher) and diluted in 5% milk, 1X 
TBS-T solution.  ECL Western Blotting Detection reagents (GE Healthcare) were used 
for developing blots onto autoradiography film.  For difficult to detect proteins 
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific) was used 
in combination with ECL. 
 
Cell viability assay 
To determine cell viability in the context of the various culture conditions we used 
a CellTiter-Glo® Luminescent Cell Viability Assay (Promega) per manufacture’s 
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protocol.  Cells were counted and plated in quadruplicate in a 96 well opaque side/clear 
bottom cell culture plates (Corning) in culture medium containing the noted 
concentration.  Luminescence measurements were captured using a Biotek® Synergy 2 
plate reader.  2-way ANOVA analysis was used to determine statistical significance. 
 
Cell cycle analysis by flow cytometry 
Cells were plated in triplicate and treated for 24 hrs with indicated drug. Cell 
cycle analysis was performed by EdU incorporation using Click-iT EdU Alexa Fluor 647 
flow assay kit (Invitrogen, catalog number C-10424) according to the manufacturer’s 
instructions.  After treatment cells were exposed to 10 µM EdU for 2h. Cells were then 
dissociated with 0.05% Trypsin/EDTA and fixed immediately, with 4% PFA, for 
incorporated EdU detection. Total DNA content was stained with propidium iodide (PI) 
at 10 µg/ml after RNase A treatment. Flow cytometry was performed on a CyAnTM ADP 
flow cytometer (Dako, Glostrup, Denmark) and data analysis was performed using 
FlowJo software (Tree Star, Inc.).  Statistical significance was measured by Student’s T-
Test. 
 
Apoptosis analysis by flow cytometry 
Cells were plated in duplicate and treated with the indicated drug for 48 hrs. 
Percentage of apoptotic cells were determined by staining with Annexin V Alexa Fluor® 
488 & PI (Dead Cell Apoptosis Kit, Invitrogen, cat# V13241) according to the 
manufacturer’s instructions. Flow was performed on a Dako CyAn ADP and data were 
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analyzed using FlowJo software.  Statistical significance was measured by Student’s T-
Test. 
 
RNAi experiments 
pLKO.1 shRNA plasmids were obtained form the UNC Viral Vector Core, 
packaged and infected per manufacture’s protocols.  Addgene catalogue numbers:  
shNS (#1864), shRictor (#1853), shRaptor (#1857), shmTOR (#1853).  Cells were 
incubated with viral media over-night, and replaced with fresh complete media.  
Selection with 1 µg/mL puromycin was started 48 hrs later.  
 
Colony formation assay 
RCC cells were plated at low-density in a 6 well plate (786-0: 50 cell/well and 
RCC4: 100 cells/well).  Cells were allowed to attach and treated with indicated drug(s).  
Treatment conditions were changed every 72 hrs.  Cells were fixed with 4% PFA and 
stained with crystal violet.   
 
TCGA data analysis 
TCGA KIRC RPPA protein data was log2 transformed and median centered.  
Tumors samples (n=454) and proteins relating to ERK and mTOR signaling were 
hierarchically clustered by centroid linkage using Cluster 3.0 and protein clusters were 
determined based on tumors sharing a common node. Mutations in mTOR related 
genes were annotated and superimposed as tracks above the heatmap for visualization. 
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Scatter and Kaplan-Meier plots were generated in R (http://cran.r-project.org).  Survival 
differences were determined by log-rank test. 
2.6	   Supplemental	  Figures	  
 
 
 
Supplemental Figure 2.1:  The indicated cell lines were treated with increasing doses 
of rapamycin (A) or BEZ235 (B) for 24 hours.  Whole cell extracts were immunoblotted 
with the indicated antibodies to evaluate changes in mTORC1 and mTORC2 signaling. 
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Supplemental Figure 2.2:  RCC10 cells were treated over the course of 4 days with 
the indicated drugs and assessed for viability using CellTiter-Glo®. 
 
 
 
 
Supplemental Figure 2.3:  RCC10 and RCC4 cells treated with rapamycin or BEZ235 
for 24 hrs and analyzed by western blot for apoptotic marker cleaved-caspase 3. 
 
 
  
63 
 
 
Supplemental Figure 2.4:  (A)  786-0 and RCC4 cells were plated and treated with a 
dose titration of BEZ235 and IC50 value determined using CellTiter-Glo® cell viability 
reagent.  (B) 786-0 and RCC4 cells were treated with 2 nM BEZ235 over a 24 hr. time 
course and immunobloted for protein expression of mTORC1, mTORC2, and MEK/ERK 
signaling proteins. 
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Supplemental Figure 2.5:  (A) 786-0 and RCC4 cells were treated with indicated drugs 
and assessed for viability on day 4 using CellTiter-Glo®.  Statistical significance was 
determined by comparing rapamycin and BEZ235 treated groups.  (B) 786-0 and RCC4 
cells were plated, allowed to attach, and treated with 200 nM rapamycin, 2 nM BEZ235, 
10 nM GSK212.  Photographs of wells containing 786-0 and RCC4 cells fixed with 4% 
PFA and stained with 0.1% crystal violet. 
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Supplemental Table 2:  Antibodies used in Chapter 2 experiments 
 
  
 
 
CHAPTER 3 
AUTOPHAGY IS A TARGETABLE COMPENSATORY SURVIVAL PATHWAY, 
INCREASED IN THE CONTEXT OF MTOR INHIBITION IN RENAL CELL 
CARCINOMA 
3.1	   Overview	  
 
The mechanistic target of rapamycin (mTOR), which exists in two independent 
complexes:  TORC1 and TORC2 has been shown to be dysregulated in renal cell 
carcinoma (RCC).  mTOR inhibition results in compensatory activation of PI3K/Akt 
survival signaling as well as autophagy.  Two allosteric mTOR inhibitors are FDA 
approved for treating advanced RCC and catalytic, active site inhibitors are in clinical 
development.  We interrogated the effects of mTOR inhibition on autophagic flux in 
RCC cell lines and compared the differential effects of allosteric versus catalytic mTOR 
inhibition.  While both allosteric and catalytic inhibition increase autophagic flux, 
catalytic mTOR inhibition did so more extensively.  Furthermore, assessment of cell 
lines with stable knock-down of Raptor or Rictor suggest that inhibition of both TORC1 
and TORC2 contribute to the increased autophagic flux induced by catalytic mTOR 
inhibition.  Finally, we show that catalytic mTOR inhibition in combination with 
autophagy inhibition increases apoptosis and reduces cellular proliferation.  In 
summary, our studies demonstrate that catalytic mTOR inhibition induces autophagic 
flux greater than allosteric mTOR inhibition and suggest that the combinatorial targeting 
of mTOR and autophagy may have therapeutic benefit in RCC. 
3.2	   Introduction	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In 2013 renal cell carcinoma accounted for approximately 14,000 deaths and 
65,000 new cases [1]. Renal cell carcinoma (RCC) can be classified into several distinct 
histological subtypes, each associated with unique genetic alterations [9].  Clear cell 
renal cell carcinoma (ccRCC) is the most common of these histological classifications 
encompassing roughly 75% of all cases of kidney cancer [6].  Clear cell renal cell 
carcinoma has been tightly linked to inactivation of the von Hippel-Lindau (VHL) tumor 
suppressor gene and patients with VHL disease are more susceptible to developing 
hereditary ccRCC and a variety of other cancers [6].  However, sporadic ccRCC cases 
can occur and are associated with biallelic inactivation of the VHL gene.  The VHL 
protein (pVHL) negatively regulates the alpha subunit of the hypoxia-inducible factor 
(HIFα) family of transcription factors (HIF1α, HIF2α, HIF3α) in a oxygen dependent 
manner via its E3 ubiquitin ligase activity [12].  Importantly, pVHL’s tumor suppressor 
function is dependent upon the downregulation of HIFα subunits and in particular HIF2α 
[20-23]. 
Stabilization of HIFα, either as a consequence of hypoxia or pVHL inactivation 
leads to transcriptional activation of numerous genes associated with tumor progression 
and tumor adaptation to a hypoxic tumor microenvironment [118] and HIFα has been 
shown to play important roles in invasion and metastases in genetically engineered 
murine models [136-138].  Currently, the drugs approved by the FDA for treating 
advanced RCC target signaling networks activated upon disruption of VHL (i.e. HIFα 
activation) [118].  Specifically, small-molecule tyrosine kinase inhibitors (e.g. sunitinib 
and pazopanib) have been established to inhibit the vascular endothelial growth factor 
receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) [118].  
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Additionally, temsirolimus and everolimus, derivatives of rapamycin, have been 
approved to treat advanced RCC [89].  Unfortunately, while mTOR inhibitors clearly 
prolong overall survival of patients with advanced RCC, actual tumor responses are 
limited [91,98].  Regardless of the selected therapeutic regimen, a high frequency of 
patients become refractory to therapy and eventually succumb to progression of 
disease, indicating potential compensatory survival and proliferative mechanisms.  
Rapamycin and its derivatives are allosteric inhibitors of the serine/threonine 
kinase, mechanistic target of rapamycin (mTOR) [35,89].  mTOR exists within two 
distinct complexes, mTORC1 and mTORC2.  Several proteins are common to both 
mTORC1 and mTORC2, such as DEP domain containing mTOR-interacting protein 
(DEPTOR), mammalian lethal with sec-13 protein 8 (mLST8), and tti1/tel2 complex.  
However, mTORC1 and mTORC2 differ in composition by several proteins.  
Regulatory-associated protein of mammalian target of rapamycin (Raptor) and proline-
rich AKT substrate 40 KDa (PRAS40) are distinct to the mTORC1 signaling complex 
while rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated 
map kinase-interacting protein1 (mSin1), and protein observed with Rictor 1 and 2 
(protor1/2) are associated with mTORC2 [36].  Notably, the mTORC2 complex and 
distinct signaling nodes of mTORC1 are thought to be relatively insensitive to rapamycin 
[38].  The inability of rapamycin and its derivatives to inhibit all signaling nodes of mTOR 
has resulted in development of catalytic mTOR inhibitors capable of attenuating 
mTOR’s kinase activity resulting in perturbation all signaling nodes of mTORC1 and 
mTORC2 complexes [90]. 
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mTOR serves as a key negative regulator of autophagy, an evolutionarily 
conserved physiological process utilized by cells to recycle damaged protein 
aggregates and faulty organelles [139,140], but also implemented in response to a 
variety of cellular stresses (low nutrient availability, low energy, and hypoxia) [47,141].  
mTOR negatively regulates autophagy induction through mTORC1’s ability to 
phosphorylate autophagy regulating protein 1 (ULK1) [48,49,107].  RCC cells have 
been stated to have high levels of autophagy [109].  While it appears that enhanced 
autophagy can function to promote cell survival in established tumors, there is also 
evidence that cancer cells can undergo autophagic cell death when autophagic flux is 
dysregulated [62,68,142,143].  Therefore, autophagy’s role in tumor progression is 
complex and likely context dependent.  
Here, we investigate, through both pharmacologic and genetic approaches, the 
effect of allosteric and catalytic mTOR inhibitors in RCC. We show evidence that 
catalytic mTOR inhibitors may induce autophagy greater than allosteric mTOR 
inhibitors.  Furthermore, we show that attenuation of this compensatory survival signal 
may increase therapeutic efficacy in RCC through attenuation of cellular proliferation 
and augmentation of cell death signals. 
3.3	   Results	  
3.3.1	   Catalytic	  mTOR	  inhibition	  induces	  autophagic	  flux	  greater	  than	  allosteric	  mTOR	  
inhibition	  in	  RCC	  
 
Several groups have shown that either allosteric or catalytic mTOR inhibition 
increase autophagic flux of cancer cells [93,103,104,109,110,144].  We wished to 
investigate whether allosteric and catalytic mTOR inhibition have differing effects on 
autophagy in the context of RCC.  Autophagy induction results in lipidation of LC3B-I 
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through the addition of a phosphatidylethanolamine (PE) moiety generating LC3B-II.  
Therefore, processing of LC3B-I to LC3B-II serves as a marker for early 
autophagosome to mature autolysosome formation [145].  We assessed the processing 
of LC3B-I to LC3B-II in RCC cell lines when treated with doses of allosteric (rapamycin) 
or catalytic (BEZ235 and AZD8055) mTOR inhibitors shown to inhibit mTOR signaling 
(Supplemental Figure 3.1).  To determine if Catalytic mTOR inhibition with AZD8055 or 
BEZ235 increased flux of autophagy relative to rapamycin treated cells we 
immunoblotted for LC3B-II (Figure 3.1A and Supplemental Figure 3.2).  To establish 
whether this increase in LC3B-II accumulation was secondary to increased 
autophagosome formation (so called “autophagic flux”) or reduced autophagosome 
degradation, we assessed the accumulation of LC3B-II in cells treated with AZD8055 
and chloroquine (CQ) or BEZ235 and CQ or relative to cells treated with rapamycin and 
CQ, suggesting that catalytic mTOR inhibition more robustly increases autophagy 
(Figure 3.1A and Supplemental Figure 3.2) [70,145].  Treatment with both AZD8055 and 
CQ or BEZ235 and CQ increased the LC3B-II to LC3B-I ratio relative to cells treated 
with rapamycin and CQ.  Therefore, catalytic mTOR inhibition increases autophagic flux 
to a greater degree than allosteric mTOR inhibition.  
To assess the effects of rapamycin and BEZ235 on autophagic flux through an 
orthogonal assay we generated 786-0 RCC cells stably expressing a tandem mCherry-
GFP-LC3 autophagy reporter, which emits dual mCherry/GFP fluorescence in early 
autophagosomes and because of pH-dependent quenching of GFP fluorescence emits 
mCherry only in mature autolysosomes.  The mCherry-GFP tandem reporter is 
therefore a faithful assessment of autophagic flux and also allows the dissection of 
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differing stages of autophagolysosome maturation.  CQ treated 786-0 cells showed 
modest induction of autophagosome formation (yellow punctae on merged images) 
while rapamycin and in particular BEZ235 treatment led to robust induction of both 
autophagosome (yellow punctae) and progression to autolysosome  (red / orange 
punctae) formation, corroborating that mTOR inhibition and in particular catalytic 
inhibition by BEZ235 induces autophagic flux (Figure 3.1B).    
Sequestosome 1(SQSTM1), also known as p62, is a protein capable of binding 
to LC3 and can serve as selective substrate capable of directing long-lived aggregated 
proteins marked with ubiquitin polymers targeting them for autophagic degradation.  
Hence, decreases in p62 protein expression can serve as a marker of functional 
autophagic flux [47,146].  In conjunction with the above findings; when RCC cells were 
treated with rapamycin or BEZ235 we observed decreases in p62 expression (Figure 
3.1C).  These data in aggregate further support that allosteric and catalytic mTOR 
inhibition induce autophagy 
mTORC1 signaling is well documented to negatively regulate autophagic flux via 
its phosphorylation of ULK1 at Ser757 [48,49] and rapamycin has been shown to 
decrease pULK1S757 in primary mouse embryonic fibroblasts  (MEFs) [48].  In keeping 
with this notion, we observed a decrease in pULK1S757 in RCC cells treated with 
BEZ235 or AZD8055 (Figure 3.1D).  In contrast and unexpectedly, we saw no change in 
pULK1S757 in two cell lines (RCC10 and UNC-R1 cells) and interestingly an increase in 
two other cell lines (786-0 and UNC-R2) when they were treated with rapamycin (Figure 
3.1D).  Similar findings in pULK1S757 have been seen in transformed cancer cells treated 
with rapamycin [107,112] raising the possibility that rapamycin dependent autophagy 
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induction is regulated through ULK1 in primary cells but through an alternative 
mechanism in cancer cells or that mTORC1’s regulation of pULK1S757 may be less 
sensitive to allosteric mTOR inhibition than catalytic mTOR inhibition, similar to the 
differences seen in the inhibition of S6K and 4E-BP1 phosphorylation. 
 
Figure 3.1:  Catalytic mTOR inhibition induces autophagic flux greater than 
allosteric mTOR inhibition. (A) RCC10 cells were treated with Rapamycin, BEZ235, 
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AZD8055 and CQ for 24 hrs and whole cell lysates were immunoblotted for mature 
autophagosome marker, LC3B-II (quantification represents LC3B-II expression 
normalized to Actin as a ratio of LC3B-II/Actin respective to control).  (B) 786-0 RCC 
cells transfected with mCh.GFP.LC3B were treated for 24 hrs. with 200 nM rapamycin, 
1 µM BEZ235, and 20 µM chloroquine and subjected to immunofluorescence analysis 
for LC3B processing evident by puncta formation (orange represents increased mature 
autolysosomes) (C) RCC cells were treated with Rapamycin, AZD8055, or BEZ235 for 
24 hrs. and analyzed by western blot for pULK1S757 (expression of pULK1S757 is a 
marker for mTOR regulated inhibition of autophagy induction).  (D) UNC-R2 RCC cells 
were treated with rapamycin, BEZ235, and CQ for 24 hrs and immmunobloted for p62 
protein expression (decreases in p62 correlates with increased autophagy).  
(quantification represents p62 expression normalized to Actin as a ratio of p62/Actin 
respective to control) 
3.3.2	   Both	  mTORC1	  and	  mTORC2	  restrain	  autophagic	  flux	  
 
The more prominent induction of autophagic flux seen by BEZ235 treatment, 
relative to rapamycin treatment could either be because of BEZ235’s ability to better 
inhibit mTORC1 signaling or because of its ability to inhibit mTORC2. To dissect the 
specific contributions of TORC1 and TORC2 on regulation of autophagy we stably 
knocked-down essential components, Raptor and Rictor, for mTORC1 and mTORC2 
signaling, respectively (Figure 3.2A and Supplemental Figure 3.3A).  As expected, given 
the well documented role of mTORC1 in negatively regulating autophagy, we noted that 
stable knock-down of Raptor resulted in increased accumulation of LC3B-II in the 
presence of CQ relative to shNS CQ treated cells (Figure 3.2B).  However, we also 
observed that knock-down of Rictor in the presence of CQ increased the levels of 
LC3B-II accumulation relative to CQ treated cells expressing shRNAs to a non-specific 
sequence.  Furthermore, we observed a decrease in p62 protein expression in cells 
stably expressing shRNA for Raptor and to a lesser extent Rictor (Figure 3.2C).  Finally, 
our data revealed a decrease in phosphorylation of ULK1 at Ser757 in cells expressing 
shRNA for Raptor and minimally for cells with shRNA for Rictor (Figure 3.2D).  These 
results, in aggregate with our pharmacologic data, suggest that both mTORC1 and 
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mTORC2 work to restrain autophagy and that the enhanced induction of autophagic flux 
seen with catalytic mTOR inhibition may in part may be mediated through its ability to 
inhibit mTORC2. Nonetheless, to fully recapitulate catalytic mTOR inhibition we 
transfected RCC cells with siRNAs for Rictor, Raptor, mTOR, or Rictor+Raptor and 
assessed processing of LC3B-I to LC3B-II.  We noted that as before, knock-down of 
Raptor or Rictor induced autophagy (Figure 3.2F: lanes 2 and 3).  In addition, knock-
down of mTOR or combined knock-down of Raptor and Rictor appeared to more 
robustly induce autophagy (lanes 4 and 5) and autophagic flux (lanes 9 and 10) (Figure 
3.2F).  Together, these data suggest a potential utility not only for mTORC1 but also 
mTORC2 in contributing to regulation of autophagic flux and lend insight into why 
catalytic mTOR inhibitors augment autophagy more than allosteric mTOR inhibitors. 
  
75 
 
Figure 3.2:  Both mTORC1 and mTORC2 regulate autophagy.  (A) Knock-down 
confirmation for 786-0 RCC cell line expressing stable shRNA for Rictor and Raptor.  
(B) Protein expression of mature autophagosome marker, LC3B-II by immunoblot, in 
cells from Figure 2A treated with late autophagy inhibitor CQ for 24 hrs.  (C) p62 protein 
expression by immunoblot for RCC4 RCC cells established  from Supplemental Figure 
3.  (quantification represents p62 expression normalized to Actin as a ratio of p62/Actin 
respective to control)  (D) pULK1S757 expression by immunoblot for RCC4 cells 
established in Supplemental Figure 3 (quantification represents pULK1S757 expression 
normalized to Actin as a ratio of pULK1S757/Actin respective to control).  (E) Knock-down 
confirmation for 786-0 RCC cells transfected with siRNA for Rictor, Raptor, mTOR, or 
Rictor+Raptor.  (F) Protein expression of mature autophagosome marker, LC3B-II by 
immunoblot, in cells from Figure 2E (quantification represents LC3B-II expression 
normalized to Actin as a ratio of LC3B-II/Actin respective to control).  (NS:  Non-
Specific, Rap:  Raptor, Ric:  Rictor)   
3.3.3	   Autophagy	  inhibition	  enhances	  the	  anti-­‐proliferative	  effects	  of	  mTOR	  inhibition	  in	  RCC	  
 
To determine the functional role of increased autophagic flux in the context of 
mTOR inhibition, we treated cells with rapamycin and BEZ235 in the presence or 
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absence of the late autophagy inhibitor, CQ, and assayed their effects on cellular 
proliferation.  Proliferation as assessed by CellTiter-Glo® showed that both allosteric 
and catalytic mTOR inhibition decreased cellular proliferation and that the effects were 
further enhanced when combined with late autophagy inhibition (Figure 3.3A).  
Additionally, bright field images of several RCC cell lines displayed a greater reduction 
in cell number after 48 hrs. of treatment when comparing combinatorial treatment 
(BEZ235 + CQ) to either single agent alone (Figure 3.3B).  Furthermore, we also saw a 
significant decrease in the percentage of cells in S-phase, when BEZ235 was combined 
with CQ in an Edu cell cycle incorporation assay (Figure 3.3C).  Finally, to dissect out 
the individual roles of mTORC1 and mTORC2 in promoting proliferation of RCC cells, 
we assessed the anti-proliferative effects of Rictor and Raptor shRNA in 786-0 cells and 
noted a significant decrease in proliferation when combined with CQ (Figure 3.3D) 
suggesting that both mTORC1 and mTORC2 contribute to the proliferation of RCC 
cells. 
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Figure 3.3:  Autophagy inhibition enhances the anti-proliferative effects of mTOR 
inhibition.  (A) Day 4 data shown for Cell-titer glo® cellular proliferation assay of RCC 
cells treated with Rapamycin, BEZ235, and chloroquine.  (B) Bright field images of RCC 
cells treated for 48 hrs with the noted treatments.  (C) RCC cells were treated for 24 hrs, 
stained for Edu and subjected to flow cytometry for percentage of cells in S-Phase.  (D) 
Day 4 data shown for Cell-Titer glo® cellular proliferation assay for RCC cells from 
Figure 2A.    
3.3.4	   Autophagy	  inhibition	  enhances	  the	  apoptotic	  effects	  of	  mTOR	  inhibition	  in	  RCC	  
 
We next wanted to determine if the decrease in cell number was solely due to a 
decrease in proliferation, but also an increase in cell death.  While independent groups 
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have demonstrated that cell death is enhanced when allosteric [109] or catalytic [93] 
mTOR inhibition is combined with autophagy inhibition (CQ) their relative efficacy has 
not been directly compared, in RCC.  We observed that autophagy inhibition enhanced 
the apoptotic effects of allosteric mTOR inhibition as defined by Annexin V+/ PI- cells, 
but that the effect was more robust when autophagy inhibition was combined with 
catalytic mTOR inhibition (Figure 3.4A).  Moreover, immunoblotting for the apoptotic 
marker cleaved-caspase 3 supported that the combination of catalytic mTOR inhibition 
with CQ is better at inducing apoptosis than allosteric mTOR inhibition with CQ (Figure 
3.4B).   
Finally, To examine the contributions of mTORC1 and mTORC2 to the observed 
apoptotic response, we examined the effects of RNAi to Rictor, Raptor, mTOR, or 
Rictor+Raptor in the presence or absence of CQ and observed that RNAi for mTOR or 
Rictor+Raptor were able to induce cleaved PARP and that the apoptotic response to 
these siRNAs was greater when combined with CQ (Figure 3.4C). These data support 
the notion that both mTOR complexes contribute to pro-survival and proliferative signals 
and that the increased therapeutic effect observed when catalytic mTOR inhibitors are 
combined with autophagy inhibition may in part be due to mTORC2’s regulation of 
autophagy. 
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Figure 3.4:  Autophagy inhibition increases the apoptotic response in conjunction 
with mTOR inhibition.  (A) RCC cells treated for 48 hrs. and analyzed by flow 
cytometry to distinguish the apoptotic fraction (Annexin V+/ PI-).  (B) UNC-R2 RCC cells 
were treated for 48 hrs. and analyzed by western blot for apoptotic marker, cleaved-
caspase-3.  (C) 786-0 RCC cells from Figure 2E were treated for 48 hrs. with the 
indicated treatments and analyzed by western blot for apoptotic marker cleaved-PARP. 
3.4	   Discussion	  
 
Several groups [93,109] have examined the effects of combined allosteric or 
catalytic mTOR inhibition in combination with inhibition of autophagy in the context of 
RCC.  Our studies however directly compare the effects of allosteric and catalytic 
mTOR inhibition on autophagy and assess their relative efficacy when combined with 
CQ.  We show that mTOR inhibition in conjunction with autophagy inhibition decreases 
cellular proliferation and increases apoptosis.  Additionally, we show that catalytic 
mTOR inhibition augments the autophagic process more than allosteric mTOR inhibition 
and offer this as a potential reason as to why catalytic mTOR inhibitors appear to more 
potently synergize with CQ. 
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Phosphorylation of ULK1 by AMPK is required for autophagy induction [49].  It is 
well understood that mTORC1 is a critical negative regulator of autophagy [139] and 
directly phosphorylates ULK1 at Ser757 [49,140].  mTOR mediated phosphorylation of 
ULK1 at Ser757 disrupts the necessary interaction between ULK1 and AMPK resulting 
in inhibition of autophagy induction [48].  Rapamycin would therefore be expected to 
inhibit ULK1S757 phosphorylation [48].  Interestingly, while previous literature has shown 
that rapamycin inhibits pULK1S757 expression in non-transformed MEFs [48], in our 
hands rapamycin either did not change, or in several cell lines actually increased 
ULK1S757 phosphorylation (Figure 3.1C).  In contrast, catalytic mTOR inhibition with 
BEZ235 or AZD8055 robustly inhibited expression of pULK1S757 (Figure 3.1C).  
Interestingly, similar findings have been observed in other cancer types where allosteric 
mTOR inhibition did not alter pULK1S757 levels in ovarian and hepatocellular cancer, 
respectiveily [107,112].  The responsiveness of pULK1S757 to BEZ235 and AZD8055 but 
not rapamycin may be due to their superior ability to inhibit mTORC1 kinase activity (as 
evidenced by their ability to decrease p4E-BP1), their ability to inhibit mTORC2, or off 
target effects [90].  Nevertheless, our data suggest that at least in transformed RCC cell 
lines, rapamycin can induce autophagy without clearly decreasing the phosphorylation 
status of the mTOR responsive residue of ULK1.  
 It is well understood that mTOR inhibition can negatively impact oxidative 
respiration and glycolysis [147-149].  However, comparison of mechanistically different 
mTOR inhibitors (i.e. rapalogs or catalytic mTOR inhibitors) and their effects on 
oxidative respiration and glycolysis has not been addressed.  One possible explanation 
for the apparent ability of rapamycin to induce autophagy without attenuating mTOR’s  
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phosphorylation of ULK1 is that allosteric mTOR inhibition has a greater affect on 
energetic stress (ie. decreased levels of ATP) than does catalytic mTOR inhibition.  This 
more profound decrease in ATP might stimulate AMPK activity leading to mTOR 
independent activation of ULK1 and subsequent autophagy induction [49].  Additional 
studies assessing energy metabolism and autophagy induction in the context of 
mechanistically different types of mTOR inhibitors will help in understanding our 
observed results. 
Knocking down essential mTORC1 and mTORC2 signaling components, Rictor 
and Raptor, respectively, led to increased autophagic flux in conjuction with decreased 
p62 levels (Figure 3.2C) and decreased pULK1S757 expression (Figure 3.2D).  This 
observation is interesting because it supports that mTORC2 may also negatively 
regulate autophagy (Figure 3.2C).  These results may explain in part why catalytic 
mTOR inhibition may increase autophagic flux greater than allosteric mTOR inhibition.  
Nonetheless, the observed decrease in pULK1S757 and p62 expression by catalytic 
mTOR inhibition correlates with the increase in LC3B-II expression observed in 
response to BEZ235 or AZD8055 relative to rapamycin. 
In summary, our studies suggest a model that catalytic mTOR inhibition 
increases autophagic flux more than allosteric mTOR inhibition because of mTORC2’s 
ability to restrain autophagic flux.  Additionally, this compensatory activation may 
function as a pro-survival and pro-proliferative signal limiting the efficacy of various 
classes of mTOR inhibition.  Herein, we demonstrate that combining mTOR inhibition 
and autophagy inhibition decreases cellular proliferation and increases cell death.   
Moreover, our data suggests that catalytic mTOR inhibition should be investigated in 
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RCC and that the compensatory upregulation of autophagy may actually be a potential 
synthetic vulnerability. 
3.5	   Materials	  and	  Methods	  
 
Cell lines and culture conditions 
RCC10, 786-0, RCC4, UNC-R1, UNC-R2 were cultured in complete DMEM 
(CORNING-Cellgro #10-013-CV) supplemented with 10%FBS, 1X Penn/Strep at 37°C, 
5% CO2, 21% O2.  786-0 cells were obtained from ATCC and RCC4 cells were a gift of 
Dr. Kimryn Rathmell [11] and RCC10 cells were obtained from Dr. Michael Ohh [135].  
UNC-R1 and UNC-R2 cell lines were generated as described in (Chapter 2:  Bailey, 
PloS One “in press”).   AZD8055 (Selleckchem), BEZ235 (Center for Integrative 
Chemical Biology & Drug Discovery, UNC Eshelman School of Pharmacy), Rapamycin 
(LC Laboratories) were dissolved in DMSO.  Chloroquine (Sigma) was dissolved into 
sterile PBS.   
 
Immunoblot conditions 
Cells were lysed in RIPA buffer complemented with Set I and Set II phosphatase 
inhibitors at 1X (Calbiochem), and protease inhibitors at 1X (Roche).  Whole cell lysate 
concentration was determined with Bio-Rad Protein Assay Dye Reagent Concentrate 
(Bio-Rad).  Proteins were resolved on SDS-PAGE gels and electrotransferred to 
nitrocellulose membranes, 0.2 µm (Bio-Rad) were used to transfer protein from SDS-
PAGE gel.  Primary antibodies pS6S235/236, pAKTS473, pAktT308, p4E-BP1T37/46, Cleaved 
PARP, LC3B, pULK1S757, p62, Rictor, Raptor, cleaved-caspase3 were from Cell 
Signaling Technologies®.  KU-80 (GeneTex #GTX70485) and Actin-HRP (Santa Cruz 
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#C-11) primary antibodies served as loading controls (LC) where noted.  Secondary 
anti-Rabbit and anti-mouse antibodies were from (Fisher) and diluted in 5% milk, 1X 
TBS-T solution.  ECL Western Blotting Detection reagents (GE Healthcare) were used 
for developing blots onto autoradiography film.  For difficult to detect proteins 
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific) was used 
in combination with ECL.   
 
Quantification of immunoblots 
Quantification of protein expression was analyzed with ImageJ software.  All 
expressed values were normalized to loading controls.  Fold change was expressed as 
a ratio of the treatment condition divided by the control condition (DMSO or shNS were 
noted). 
 
Measuring autophagosomes by confocal microscopy 
The mCherry-GFP-LC3B cDNA was PCR’d from Addgene #22418 plasmid using 
primers containing EcoRI and BamHI sites.  The PCR product was TOPO cloned into 
pCR®-Blunt II-TOPO (Invitrogen).  The EcoRI and BamHI product was then cut and put 
into pCDH EF1 IRES puro into the EcoRI and BamHI sites.  RCC cells were stably 
transfected with this lentivirial vector and selected with 1 µg/mL puromycin. 
Stably transfected RCC cells were treated for 24 hrs. then fixed with 4% PFA.  Cells 
were then stained with Phalloidin 647:  #A22287 from life technologies 1:40 dilution of 
stock, DAPI: Invitrogen molecular probes #D3571 1:10,000 of 10mg/ml stock for 20 min 
at room temperature and mounted with fluorosave  (Millpore #345789).  Cells were 
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imaged using the Zeiss 710 confocal microscope at the Microscopy Services Laboratory 
at UNC-CH. 
 
Cell viability assay 
To determine cell viability in the context of the various culture conditions we used 
a CellTiter-Glo® Luminescent Cell Viability Assay (Promega) per manufacture’s 
protocol.  Cells were counted and plated in a 96 well opaque side/clear bottom cell 
culture plates (Corning) in culture medium containing the noted concentration. 
Measurements were taken using a Biotek® Synergy 2 plate reader. 2-way ANOVA 
analysis was used to determine statistical significance. 
 
Cell cycle analysis by flow cytometry 
  Cells were plated in triplicate and treated for 24 hrs with indicated drug. Cell 
cycle analysis was performed as in [150].   
 
Apoptosis analysis by flow cytometry 
Cells were plated in duplicate and treated with the indicated drug for 48 hrs. 
Percentage of apoptotic cells were determined by staining with Annexin V Alexa Fluor® 
488 & PI (Dead Cell Apoptosis Kit, Invitrogen, cat# V13241) according to the 
manufacturer’s instructions. Flow was performed on a Dako CyAn ADP and data were 
analyzed using FlowJo software.  Statistical significance was measured by Student T-
Test. 
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RNAi experiments 
siNS (#4390844) simTOR (#4390824 – ID:s603) siRictor (#4392420 – ID:s226001), 
Raptor (#4392420 – ID:s33215) were all purchased from Ambion®, and  RCC cells 
were transfected with X-tremeGENE 9 DNA Transfection Reagent (#06365787001) 
from Roche as per manufactures protocol.  pLKO.1 shRNA plasmids were obtained 
form the UNC Viral Vector Core, packaged and infected per manufacture’s protocols.  
Addgene catalogue numbers:  shNS (#1864), shRictor (#1853), shRaptor (#1857), 
shmTOR (#1853).  Cells were incubated with viral media over-night, and replaced with 
fresh complete media.  Selection with 1 µg/mL puromycin was started 48 hrs later. 
3.6	   Supplemental	  Figures	  
 
 
 
Supplemental Figure 3.1:  RCC cells were treated for 24 hrs with DMSO (control), 
rapamycin 200 nM, BEZ235 1 µM, AZD8055 500 nM and whole cell lysate was 
immunblotted for mTORC1 and mTORC2 signaling inhibition 
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Supplemental Figure 3.2:  UNC-R2 RCC cells were treated for 24 hrs. with the 
indicated drugs and whole cell lysate was immunoblotted for LC3B-II protein expression 
(quantification represents LC3B-II expression normalized to Actin as a ratio of LC3B-
II/Actin respective to control). 
 
 
 
 
Supplemental Figure 3.3:  Confirmed KD for RCC4 cells expressing stable shRNA for 
Rictor, Raptor, or NS (Non-Specific). 
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CHAPTER 4 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
4.1	   Compensatory	  pathway	  activation	  and	  potential	  molecular	  mechanisms	  
induced	  by	  mTOR	  inhibition	  in	  RCC	  
 
In the context of mTOR inhibition we observed compensatory activation of both 
MEK/ERK and autophagy signaling pathways.  Activation of these pathways supported 
the notion that combinatorial-targeted inhibition may increase efficacy of mTOR 
inhibition.  Not only did we show that combining mTOR inhibition with either MEK or 
autophagy inhibition could increase efficacy over mTOR inhibition alone; we additionally 
showed that allosteric and catalytic mTOR inhibition had varying effects on activation of 
these pathways. 
Our observation of increased MEK activation in the context of mTOR inhibition 
has been observed in other cancer types [102,105,116,122,123,131,151,152].  Early 
studies by Carrecedo et al. demonstrated that rapamycin inhibition lead to 
compensatory activation of MEK/ERK signaling, through a S6K/PI3K-dependent 
mechanism [101].  However, emphasis on additional mTORC1 signaling node 
regulating phosphorylation of 4E-BP1 was not investigated by Carrecedo et al.    
Several groups have observed increases in MEK/ERK signaling in the context of 
catalytic mTOR inhibitors [102,105,106].  Inhibition of 4E-BP1 phosphorylation by 
catalytic mTOR inhibitors serves as a potential mechanism for compensatory MEK/ERK 
signaling by catalytic inhibition of mTOR [105]. Notably allosteric mTOR inhibitors do not 
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affect 4E-BP1 phosphorylation.  We have presented RNAi data supporting that inhibition 
of mTORC1, through knock-down of Raptor is capable of increasing MEK signaling as 
shown by increases in phosphorylation of ERK and downstream effector, p90RSK (data 
not shown). 
In our hands, we have observed that mTOR inhibitors increase phosphorylation 
of ERK effector and downstream effector p90RSK.  p90RSK is an AGC kinase that is 
capable of phosphorylating BCL2-associated agonist of cell death (BAD).  
Hyperphosphorylated BAD is recognized by 14-3-3 proteins resulting in sequestration of 
BAD in the cytosol and away from pro-survival BCL2 family proteins.  Treatment of lung 
cancer cells with rapamycin has been shown to induce phosphorylation of ERK and 
BAD and this phosphorylation serves as a resistance mechanism to rapamycin 
treatment [116].  Hypophosphorylated BAD functions as a pro-apoptotic protein through 
disruption of pro-survival BCL2 family proteins with BAX and BAK [115].  This disruption 
results in BAX and BAK being able to localize to the mitochondria to induce an apoptotic 
cascade.   
In RCC cells, we have demonstrated that mTOR inhibition induces 
compensatory, therapeutically targetable activation of MEK/ERK signaling.  Combining 
MEK inhibitor, GSK212, with rapamycin or BEZ235 increases therapeutic efficacy 
through attenuated cellular proliferation and increases in an apoptotic response.  We 
have preliminary data supporting that the increase in apoptosis may be through 
GSK212’s ability to decrease phosphorylation of BAD at ser 112 (data not shown).  
Unfortunately, BAD is a substrate of other AGC kinases.  Specifically, AKT and S6K are 
both capable of contributing to the hypersphorylated state of BAD, through 
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phosphorylation of BAD at ser 136 [115].  It is unclear the exact phosphorylation status 
of BAD that is required for its role in regulating apoptosis, and would be an area of 
needed investigation in deciphering a more clear mechanism behind the efficacy 
observed with mTOR and MEK inhibition in RCC.   
Pharmacologically, we observed that treatment with catalytic mTOR inhibition 
increased autophagic flux greater than allosteric mTOR inhibition.  While this finding 
may be a result of more potent inhibition of mTORC1 activity by catalytic mTOR 
inhibition we also investigated whether catalytic mTOR inhibition more robustly induced 
autophagy secondary to its ability to inhibit mTORC2.  Specifically, we demonstrated 
genetically that mTORC2 plays a direct role in regulating autophagy.  Nonetheless, a 
detailed mechanism as to how catalytic mTOR inhibition causes increased autophagic 
flux greater than allosteric mTOR inhibition needs to be investigated.  For example, 
mTORC2’s regulation/phosphorylation of essential autophagy inducing genes (ULK1) 
may be a plausible component within this proposed mechanism. 
Autophagy and proteosomal degradation are tightly linked degradative processes 
for post-translational regulation of proteins [153].  HIF2α levels are primarily regulated in 
a pVHL and proteasome dependent manner.  More recently, HIF2α has been shown to 
be targeted for autophagic degradation but only in the context of intact pVHL [154].  
However, while Liu et al. show data indicating that autophagy may have a tumor 
suppressive role in ccRCC, they do not show a direct relation of autophagy promoting 
ccRCC tumorogenesis in RCC cells lacking functional VHL.  Furthermore, our data 
indicates the increased autophagy observed with mTOR inhibition is targetable and 
increases the efficacy observed with various types of mTOR inhibitors. 
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It is well understood that mitochondria contribute to ROS production and the 
number of mitochondria and levels of reactive oxygen species (ROS) is tightly regulated 
by the cell [155].  However, damaged mitochondria or increases in mitochondrial 
number can increase ROS production resulting in increases in autophagy [156].  The 
increase in autophagy is thought to eliminate damaged mitochondria and possibly 
oxidized proteins to help reduce ROS levels in effort to regulate cellular homeostasis.  
Interestingly, in RCC cells, it has been shown that allosteric mTOR inhibitor, CCI-779 is 
capable of increasing ROS and that treatment with chloroquine further augments ROS 
accumulation [109].  Bray and colleagues also demonstrated that the combination of 
CCI-779 with chloroquine increased cytotoxicity which is in part due to the increase in 
ROS species and a cell death program involving necroptosis [109].  The effect of ROS 
production by catalytic mTOR inhibition has not been thoroughly investigated in RCC, 
however we have observed an increase in heme oxygenase decycling1 (HMOX-1), an 
enzyme that correlates with increases in oxidative stress [157], also known as HO-1  in 
RCC cells treated with BEZ235 (data not shown). We also noticed further increases in 
HO-1 expression when BEZ235 was combined with chloroquine (data not shown) 
supporting the observation by Bray et al. that combining autophagy inhibition in 
combination with mTOR inhibition increases ROS levels.  While Bray et al. did not 
observe induction of apoptosis or autophagic cell death as the cell death program 
induced by combined mTOR and autophagy inhibition, others have described 
compounds that increase autophagy in VHL null RCC cell lines leading to autophagic 
cell death [143].  Moreover, when combining BEZ235 and CQ we observed increases in 
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an apoptotic response, but it is important to note that we did not investigate necroptosis 
as a potential mechanism of cell death in our context.   
Most importantly, autophagic, necroptotic, and apoptotic programmed cell death 
may be interlinked [64,158,159], and most likely share molecular pathways resulting in 
troublesome determination of which pathway oversees cell death as the final outcome.  
Therefore, it is important to understand, in which cellular context, which cell death 
pathway(s) are capable of being activated with the selected therapeutic combination. 
In summary, the data presented shows genetic and pharmacological evidence for 
compensatory survival and proliferation pathway activation by mTOR inhibition.  
Specifically, we addressed AKT, MEK/ERK, and autophagy pathway activation as 
targetable compensatory pathways in the context various classes of mTOR inhibitors.  
We demonstrated that co-targeting mTOR and the noted compensatory pathways 
yielded increased efficacy at inhibiting cellular proliferation and/or augmenting 
apoptosis.  Together, recent KIRC_TCGA RPPA data and our new understanding of the 
molecular and functional consequences of various types of mTOR inhibition in treating 
advanced ccRCC will help aid clinicians in stratifying patients who may benefit best due 
to potential oncogenic pathways addiction. 
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